6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2022

Commission File Number: 001-39316

BURNING ROCK BIOTECH LIMITED

(Registrant’s Name)

No.5 Xingdao Ring Road North, International Bio Island

Guangzhou, Guangdong

People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒                     Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

EXHIBIT INDEX

This current report on Form 6-K, including Exhibits 99.1 and 99.2 to it, shall be incorporated by reference into the Registrant’s registration statement on Form F-3, which became effective on September 30, 2022 (File no. 333-264577), and be a part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently furnished.

Number	Description of Document
99.1	Management’s Discussion and Analysis of Financial Condition and Results of Operations and Recent Developments
99.2	Unaudited Condensed Consolidated Financial Statements

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Burning Rock Biotech Limited
By:	/s/ Leo Li
Name:	Leo Li
Title:	Chief Financial Officer

Date: November 7, 2022

3

EX-99.1

Exhibit 99.1

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Discussion and analysis below are limited to the operations of Burning Rock Biotech Limited (“we” or “us”).

Summary Consolidated Financial and Operating Data

The summary unaudited interim consolidated financial information for the six months ended June 30, 2021 and 2022 and as of June 30, 2022 has been derived from our unaudited interim condensed consolidated financial statements as of and for the six months ended June 30, 2022 included elsewhere in this current report. Our unaudited interim condensed consolidated financial statements have been prepared on a basis consistent with our audited consolidated financial statements. The summary consolidated balance sheet data as of December 31, 2021 has been derived from our audited consolidated financial statements included in our annual report on Form 20-F for the year ended December 31, 2021 filed with the SEC on April 29, 2022 (our “2021 Form 20-F”). The summary consolidated financial data should be read in conjunction with those financial statements and the accompanying notes and “Item 5. Operating and Financial Review and Prospects” included in our 2021 Form 20-F.

Summary Unaudited Consolidated Statements of Comprehensive Loss Data

	Six months ended June 30,
	2021			2022
	RMB’000			RMB’000			US$’000
Revenues:
Revenues from services		164,414			185,581			27,707
Revenues from sales of products		69,488			80,789			12,061
Total revenues		233,902			266,370			39,768
Cost of revenues(1)
Cost of services		(46,731	)		(66,462	)		(9,923	)
Cost of goods		(20,000	)		(29,726	)		(4,438	)
Total cost of revenues		(66,731	)		(96,188	)		(14,361	)
Gross profit		167,171			170,182			25,407
Operating expenses:
Research and development expenses(1)		(185,485	)		(211,608	)		(31,592	)
Selling and marketing expenses(1)		(123,188	)		(194,845	)		(29,090	)
General and administrative expenses(1)		(232,389	)		(292,049	)		(43,602	)
Total operating expenses		(541,062	)		(698,502	)		(104,284	)
Loss from operations		(373,891	)		(528,320	)		(78,877	)
Interest income		1,468			4,517			674
Interest expenses		(1,075	)		90			13
Other income, net		551			425			63
Foreign exchange loss, net		(503	)		(153	)		(23	)
Loss before income tax		(373,450	)		(523,441	)		(78,150	)
Income tax expenses		(1,626	)		(84	)		(13	)
Net loss		(375,076	)		(523,525	)		(78,163	)

(1) Share-based compensation expenses were allocated as follows:

	Six months ended June 30,
	2021		2022
	RMB’000		RMB’000		US$’000
Cost of revenues		745		806		120
Research and development expenses		43,230		24,222		3,616
Selling and marketing expenses		5,442		3,932		587
General and administrative expenses		118,750		128,330		19,159
Total		168,167		157,290		23,482

Summary Condensed Consolidated Balance Sheets Data

	As of December 31, 2021		As of June 30, 2022
	RMB’000		RMB’000		US$’000
Total current assets		1,820,946		1,463,085		218,436
Total assets		2,278,587		1,861,274		277,882
Total current liabilities		372,184		359,450		53,664
Total liabilities		433,276		429,041		64,054
Net current assets		1,448,762		1,103,635		164,772
Total shareholders’ equity		1,845,311		1,432,233		213,828
Total liabilities and shareholders’ equity		2,278,587		1,861,274		277,882

Summary Unaudited Statement of Cash Flows Data

	Six months ended June 30,
	2021			2022
	RMB’000			RMB’000			US$’000
Net cash used in operating activities		(232,143	)		(253,634	)		(37,871	)
Net cash generated from investing activities		220,752			17,718			2,649
Net cash used in financing activities		(13,123	)		(73,493	)		(10,971	)
Effect of exchange rate on cash and cash equivalents and restricted cash		(17,427	)		23,347			3,485
Net decrease in cash, cash equivalents and restricted cash		(41,941	)		(286,062	)		(42,708	)
Cash, cash equivalents and restricted cash at the beginning of period		1,925,206			1,439,112			214,854
Cash, cash equivalents and restricted cash at the end of period		1,883,265			1,153,050			172,146

Operating Data

	As of June 30,
	2021		2022
In-hospital Channel:
Pipeline partner hospitals(1)		22		25
Contracted partner hospitals(2)		34		43
Total number of partner hospitals		56		68

(1) Refers to hospitals that are in the process of establishing in-hospital laboratories, laboratory equipment procurement or installation, staff training or pilot testing using our products.

(2) Refers to hospitals that have entered into contracts to purchase our products for use on a recurring basis in their respective in-hospital laboratories we helped them establish. Kit revenue is generated from contracted hospitals.

2

Results of Operations

Six Months Ended June 30, 2022 Compared to Six Months Ended June 30, 2021

Revenues

Our revenues increased by 13.9% to RMB266.4 million (US$39.8 million) for the six months ended June 30, 2022, from RMB233.9 million for the same period of 2021, primarily attributable to an increase in revenues from sales of products to RMB80.8 million (US$12.1 million) for the six months ended June 30, 2022 from RMB69.5 million for the same period of 2021 and to a lesser extent, revenues generated from services to RMB185.6 million (US$27.7 million) for the six months ended June 30, 2022 from RMB164.4 million for the same period of 2021.

The tables below set forth a breakdown by business segment of our revenues in absolute amount and as a percentage of our total revenues for the periods indicated:

	Six months ended June 30, 2021
	Central laboratory business				In-hospital business				Pharma research and development services				Total revenues
	RMB		% of total revenues		RMB		% of total revenues		RMB		% of total revenues		RMB		% of total revenues
	(in thousands, except for%)
Revenues from services		154,560		66.1		8		—		9,846		4.2		164,414		70.3
Revenues from sales of products		—		—		69,488		29.7		—		—		69,488		29.7
		154,560		66.1		69,496		29.7		9,846		4.2		233,902		100.0

	Six months ended June 30, 2022
	Central laboratory business						In-hospital business						Pharma research and development services						Total revenues
	RMB		US$		% of total revenues		RMB		US$		% of total revenues		RMB		US$		% of total revenues		RMB		US$		% of total revenues
	(in thousands, except for %)
Revenues from services		152,808		22,814		57.4		2,345		350		0.9		30,428		4,543		11.4		185,581		27,707		69.7
Revenues from sales of products		—		—		—		80,789		12,061		30.3		—		—		—		80,789		12,061		30.3
		152,808		22,814		57.4		83,134		12,411		31.2		30,428		4,543		11.4		266,370		39,768		100.0

The increase in revenues from the six months ended June 30, 2021 to the same period of 2022 was primarily due to an increase in revenues from our in-hospital business and pharma research and development services.

• Central laboratory business. Revenue generated from central laboratory business decreased slightly to RMB152.8 million (US$22.8 million) for the six months ended June 30, 2022 from RMB154.6 million for the same period of 2021, primarily attributable to the decrease in testing volume in Shanghai and Beijing due to COVID-19 related lockdowns and other restrictive measures, offset in part by growth of our newly launched products.

• In-hospital business. Revenue generated from in-hospital business increased by 19.6% to RMB83.1 million (US$12.4 million) for the six months ended June 30, 2022 from RMB69.5 million for the six months ended June 30, 2021, primarily attributable to in-hospital testing volume growth in the first quarter of 2022, offset in part by severe declines in testing volume in the second quarter of 2022 in Shanghai and Beijing due to the adverse impact of COVID-19. The number of our contracted partner hospitals increased from 34 as of June 30, 2021 to 43 as of June 30, 2022.

3

• Pharma research and development services. Revenue generated from pharma research and development services increased substantially to RMB30.4 million (US$4.5 million) for the six months ended June 30, 2022 from RMB9.8 million for the six months ended June 30, 2021, primarily attributable to increased testing performed for our pharma customers under our contracted pharma service projects.

Cost of Revenues

Our cost of revenues increased by 44.1% to RMB96.2 million (US$14.4 million) for the six months ended June 30, 2022 from RMB66.7 million for the same period of 2021. This increase was primarily attributable to an increase in cost of goods sold to RMB29.7 million (US$4.4 million) for the six months ended June 30, 2022 from RMB20.0 million for the same period of 2021, and to a lesser extent, an increase in cost of services to RMB66.5 million (US$9.9 million) for the six months ended June 30, 2022 from RMB46.7 million for the same period of 2021.

The table below sets forth a breakdown of our cost of revenue by business segment for the periods indicated:

	Six months ended June 30,
	2021		2022
	RMB’000		RMB’000		US$’000
Cost of Revenues
Central laboratory business		40,667		44,659		6,668
In-hospital business		20,000		29,726		4,438
Pharma research and development services		6,064		21,803		3,255
Total		66,731		96,188		14,361

The increase in cost of revenues from the six months ended June 30, 2021 to the same period of 2022 was primarily due to an increase in cost of revenues for our in-hospital business and pharma research and development services.

• Central laboratory business. Cost of revenue for central laboratory business was RMB44.7 million (US$6.7 million) for the six months ended June 30, 2022, representing a 9.8% increase from RMB40.7 million for the same period in 2021, primarily due to (i) rental and renovation depreciation in relation to a new building that we commenced use in January 2022, including for our central laboratory business, and (ii) increased inventory provisions for testing kits that were approaching expiration dates as a result of the decrease in the testing volume due to the adverse impact of COVID-19.

• In-hospital business. Cost of revenue for in-hospital business was RMB29.7 million (US$4.4 million) for the six months ended June 30, 2022, representing a 48.6% increase from RMB20.0 million for the same period in 2021, primarily due to an increase in testing volume as well as rental and renovation depreciation in relation to a new building that we commenced use in January 2022, including for our in-hospital business.

• Pharma research and development services. Cost of revenue for pharma research and development services was RMB21.8 million (US$3.3 million) for the six months ended June 30, 2022, representing a substantial increase from RMB6.1 million for the same period in 2021, primarily attributable to the increased depreciation and staff cost in relation to our U.S. laboratory as it started to conduct testing for pharma research and development projects from December 2021.

4

Gross Profit and Gross Margin

Our gross profit increased by 1.8% to RMB170.2 million (US$25.4 million) for the six months ended June 30, 2022 from RMB167.2 million for the same period of 2021, primarily due to the growth of our pharma research and development business. Our gross margin decreased to 63.9% for the six months ended June 30, 2022 from 71.5% for the same period of 2021.

The table below sets forth a breakdown of our gross profit and gross profit margin by business segment for the periods indicated:

	Six months ended June 30,
	2021				2022
	RMB’000		Gross profit margin (%)		RMB’000		US$’000		Gross profit margin (%)
Gross Profit and Gross Margin
Central laboratory business		113,893		73.7		108,149		16,146		70.8
In-hospital business		49,496		71.2		53,408		7,974		64.2
Pharma research and development services		3,782		38.4		8,625		1,288		28.3
Total		167,171		71.5		170,182		25,407		63.9

• Central laboratory business. Gross profit for central laboratory business was RMB108.1 million (US$16.1 million) for the six months ended June 30, 2022, representing a 5.0% decrease from RMB113.9 million for the same period of 2021, primarily attributable to the adverse impact of COVID-19. Our gross margin for central laboratory business decreased to 70.8% for the six months ended June 30, 2022 from 73.7% for the same period of 2021, primarily due to increases in cost of revenues as a result of: (i) rental and depreciation in relation to a new building that we commenced use in January 2022, including for our central laboratory business, and (ii) increased inventory provisions for testing kits that were approaching expiration dates as a result of the decrease in the testing volume due to the adverse impact of COVID-19.

• In-hospital business. Gross profit for in-hospital business was RMB53.4 million (US$8.0 million) for the six months ended June 30, 2022, representing a 7.9% increase from RMB49.5 million for the same period of 2021, primarily attributable to the continued business growth of this segment. Our gross margin for in-hospital business decreased to 64.2% for the six months ended June 30, 2022 from 71.2% for the same period of 2021, primarily due to (i) the decreased proportion of testing we provided to certain hospitals that had higher gross profit margins, and (ii) rental and depreciation in relation to a new building that we commenced use in January 2022, including for our in-hospital business.

• Pharma research and development services. Gross profit for pharma research and development services was RMB8.6 million (US$1.3 million) for the six months ended June 30, 2022, representing a 126.3% increase from RMB3.8 million for the same period of 2021, primarily attributable to the growth of this segment, partially offset by increased depreciation and staff cost in relation to our newly established laboratory in the U.S. Our gross margin for pharma research and development services decreased to 28.3% for the six months ended June 30, 2022 from 38.4% for the same period in 2021, primarily due to increased depreciation and staff cost in relation to our newly established laboratory in the U.S.

5

Operating Expenses

Research and development expenses

Our research and development expenses increased by 14.1% to RMB211.6 million (US$31.6 million) for the six months ended June 30, 2022 from RMB185.5 million for the same period of 2021, primarily due to an increase in staff cost for our research and development personnel and increased research and development activities for early cancer detection.

Selling and marketing expenses

Our selling and marketing expenses increased by 58.2% to RMB194.8 million (US$29.1 million) for the six months ended June 30, 2022 from RMB123.2 million for the six months ended June 30, 2021, primarily due to (i) an increase in staff cost resulting from an increase in headcount; and (ii) an increase in marketing related expenditures, such as entertainment, conference and marketing expenses.

General and administrative expenses

Our general and administrative expenses increased by 25.7% to RMB292.0 million (US$43.6 million) for the six months ended June 30, 2022 from RMB232.4 million for the six months ended June 30, 2021, primarily due to (i) an increase in staff cost resulting from increased headcount; (ii) an increase in depreciation expenses for new office space; and (iii) an increase in allowance for doubtful account in relation to accounts receivables.

Interest Income, Net

Our interest income, net increased substantially to RMB4.6 million (US$0.7 million) for the six months ended June 30, 2022 from RMB0.4 million for the same period of 2021, primarily due to an increase in average balance of short-term investment and cash and cash equivalent.

Net Loss

Our net loss increased by 39.6% to RMB523.5 million (US$78.2 million) for the six months ended June 30, 2022 from RMB375.1 million for the six months ended June 30, 2021, primarily due to a decrease in gross profit margin and increases in operating expenses discussed above, offset in part by an increase in our total revenues.

Liquidity and Capital Resources

As of June 30, 2022, we had (i) cash and cash equivalents of RMB1,148.6 million (US$171.5 million), consisting of bank deposits, and (ii) restricted cash of RMB4.5 million (US$0.7 million). We believe that our cash and cash equivalents, together with our cash generated from financing activities, our initial public offering and concurrent private placement, will be sufficient to meet our current and anticipated needs for general corporate purposes for at least the next 12 months. We may, however, decide to expand our business through additional equity and debt financing. The issuance and sale of additional equity would result in further dilution to our shareholders. The incurrence of indebtedness would result in increased fixed obligations and could result in operating covenants that would restrict our operations.

6

Cash Flows

Net cash used in operating activities for the six months ended June 30, 2022 was RMB253.6 million (US$37.9 million), while our net loss for the same period was RMB523.5 million (US$78.2 million). The difference was primarily due to adjustment for non-cash and non-operating items of RMB262.1 million (US$39.1 million), primarily including share-based compensation of RMB157.3 million (US$23.5 million), depreciation and amortization of RMB60.2 million (US$9.0 million), non-cash lease expense of RMB19.7 million (US$2.9 million), and changes in working capital. The changes in working capital primarily reflected (i) an increase in prepayment and other current assets of RMB25.6 million (US$3.8 million), primarily attributable to the payment of royalty fee and human resources outsourcing service fee and (ii) an increase in deferred revenue of RMB20.2 million (US$3.0 million) primarily as a result of our overall business growth. These factors were partially offset by (i) a decrease in accrued liabilities and other current liabilities of RMB29.5 million (US$4.4 million) primarily attributable to our decreased payroll payables; (ii) a decrease in operating lease liabilities of RMB19.6 million (US$2.9 million) primarily as a result of adoption of ASC842, the new lease accounting principle; and (iii) an increase in accounts receivables of RMB14.4 million (US$2.2 million), primarily attributable to the continued growth of our in-hospital business.

Net cash generated from investing activities for the six months ended June 30, 2022 was RMB17.7 million (US$2.6 million), primarily due to proceeds from maturity of short-term investment of RMB65.6 million (US$9.8 million), partially offset by purchase of property and equipment of RMB35.1 million (US$5.2 million) and prepayment of property and equipment and intangible assets of RMB7.9 million (US$1.2 million).

Net cash used in financing activities for the six months ended June 30, 2022 was RMB73.5 million (US$11.0 million), primarily due to the cash outflow for purchase of equity forwards of RMB66.9 million (US$10.0 million).

Recent Developments

In June 2022, our board of directors (the “Board”) authorized a share repurchase plan under which we may repurchase our Class A ordinary shares in the form of American depositary shares (“ADSs”) with an aggregate value of up to US$10 million during a 12-month period (the “Share Repurchase Program”). We have completed the Share Repurchase Program in full by repurchasing a total of 3,023,138 Class A ordinary shares in the form of ADSs.

In June 2022, Mr. Jing Rong resigned as a director from the Board, and we appointed Dr. Licen Lisa Xu as an independent director to the Board.

In July 2022, Ms. Yunxia Yang resigned as a director from the Board and a member of the compensation committee of the Board. Mr. Feng Deng, an existing director of the Board, has been appointed as a new member to the compensation committee to fill the vacancy created by Ms. Yang’s resignation.

In October 2022, we applied for admission of the ADSs to the standard listing segment of the Official List of the Financial Conduct Authority (the “FCA”) and to trading on the Main Market of the London Stock Exchange (the “LSE”) by way of a direct listing (the “Direct Listing”). The registration document and prospectus that were prepared in connection with the Direct Listing were approved by the FCA on October 21, 2022 and October 27, 2022, respectively. Trading of our ADSs on the LSE commenced on November 1, 2022, under the symbol “BNR.” The ADSs listed on the LSE are fully fungible with the ADSs listed on NASDAQ. Custodial and depositary links have been established between Euroclear, Clearstream and The Depository Trust Company to facilitate the cross-market transfers of the ADSs associated with secondary market trading.

7

2022 Long-Term Equity Incentive Plan

In July 2022, our board of directors approved the 2022 Long-term Equity Incentive Plan, or the 2022 Plan, which was subsequently approved by the shareholders of our company at the annual general meeting in September 2022. The 2022 Plan replaces our 2021 Long-term Equity Incentive Plan and the share incentive awards granted thereunder. The 2022 Plan will grant options to senior management and employees. The maximum number of shares that may be issued pursuant to all awards under the 2022 Plan is 11,775,525 Class A ordinary shares (the “Awards”), which represents approximately 9% of our current total outstanding shares on a converted and fully diluted basis.

The following paragraphs describe the principal terms of the 2022 Plan:

Type of awards. The 2022 Plan permits the awards of options.

Allocation and Plan administration. The Awards consist of three tranches of options (the “Pool I Awards,” “Pool II Awards” and “Pool III Awards”). The Pool I Awards, which represent options to purchase 1.65% of our total outstanding number of shares on an as converted and fully diluted basis, or 2,158,846 Class A ordinary shares, will be granted to our officers and employees. Mr. Yusheng Han, our chairman and CEO, will not be granted any awards of options under the Pool I Awards. The Pool II Awards represent options to purchase 4.35% of our total outstanding number of shares on an as converted and fully diluted basis, or 5,691,504 Class A ordinary shares, 62.07% (or option to purchase 3,532,658 Class A ordinary shares) of which will be granted to Mr. Yusheng Han, and the rest to other officers and employees. The Pool III Awards represent options to purchase 3% of our total outstanding number of shares on an as converted and fully diluted basis, or 3,925,175 Class A ordinary shares, 45% (or option to purchase 3,532,658 Class A ordinary shares) of which will be granted to Mr. Yusheng Han, and the rest to other officers and employees.

Award agreement. Awards granted under the 2022 Plan are evidenced by an award agreement that sets forth terms, conditions and limitations for each award, which may include the term of the award, the provisions applicable in the event of the grantee’s employment or service terminates, and our authority to unilaterally or bilaterally amend, modify, suspend, cancel or rescind the award.

Eligibility. We may grant awards to senior management and employees of our company under the 2022 Plan.

Vesting schedule.

Pool I Awards

The Pool I Awards will vest once (a) our valuation (based on the 60-day average closing share price of our publicly traded shares) reaches US$2 billion by the fifth anniversary of the grant date the Pool I valuation target is achieved, and the remaining 60% of the Pool I Awards will vest once (a) the Pool I valuation target has been achieved, (b) the grantee remains employed by us at the time when the Pool I valuation target is achieved, and (c) the grantee has been employed by us for five (5) years after the date of grant.

Pool II Awards

40% of the Pool II Awards will vest once (a) our valuation (based on the 60-day average closing share price of our publicly traded shares) reaches US$4 billion by the seventh anniversary of the grant date (the “Pool II valuation target”), and (b) the grantee remains employed by us at the time when the Pool II valuation target is achieved, and the remaining 60% of the Pool II Awards will vest once (a) the Pool II valuation target has been achieved, (b) the grantee remains employed by us at the time when the Pool II valuation target is achieved, and (c) the grantee has been employed by us for five (5) years after the date of grant.

8

Pool III Awards

40% of the Pool III Awards will vest once (a) our valuation (based on the 60-day average closing share price of our publicly traded shares) reaches US$10 billion by the seventh anniversary of the grant date (the “Pool III valuation target”), and (b) the grantee remains employed by us at the time when the Pool III valuation target is achieved, and the remaining 60% of the Pool III Awards will vest once (a) the Pool III valuation target has been achieved, (b) the grantee remains employed by us at the time when the Pool III valuation target is achieved, and (c) the grantee has been employed by us for five (5) years after the date of grant.

Exercise of options. The grantee can exercise the vested portion of options granted under the 2022 Plan at any time but no more than ten years after the grant date. The exercise price of the Awards shall be US$3.33 per share, which is equivalent to our 60-day average closing share price immediately prior to September 8, 2022, the date of shareholder approval.

Transfer Restrictions. Awards may not be transferred in any manner by the participant other than in accordance with the exceptions provided in the 2022 Plan or the relevant award agreement or otherwise determined by the Compensation Committee, such as transfers by will or the laws of descent and distribution.

Termination and Amendment. Our board of directors has the authority to amend or terminate the 2022 Plan, but no amendments, alternation or discontinuation shall be made by the board of director, (a) without the approval (but only to extent such approval is required by the principal national securities exchange on which our shares are listed or admitted to trading, and subject to certain other exceptions) of the shareholders of our company, if such action would increase the total number of shares reserved for the purposes of our 2022 Plan or change the maximum number of shares for which awards may be granted to any participant under the 2022 Plan, or (b) if such action may diminish any of the rights of the participant under any award pursuant to the 2022 Plan unless agreed by the participant. In addition, the Awards that have already been allocated can only be amended at a shareholders’ general meeting, at which meeting our C-level officers and/or entities they beneficially own shall abstain from voting.

As of September 30, 2022, there were 9,184,923 ordinary shares underlying outstanding options granted to our executive officers and employees under the 2022 Plan.

Currency Convenience Translation

The conversion of Renminbi into U.S. dollars herein, made solely for the convenience of the readers, is based on the noon buying rate in the city of New York for cable transfers of Renminbi as certified for customs purposes by the Federal Reserve Bank of New York as of June 30, 2022, which was RMB6.6981 to US$1.00. No representation is intended to imply that the Renminbi amounts could have been, or could be, converted, realized, or settled into U.S. dollars at that rate or any other rate. The percentages stated herein are calculated based on Renminbi.

9

EX-99.2

Exhibit 99.2

BURNING ROCK BIOTECH LIMITED

INDEX TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

	PAGES
Condensed Consolidated Balance Sheets as of December 31, 2021 and June 30, 2022		F-2
Condensed Consolidated Statements of Comprehensive Loss for the six months ended June 30, 2021 and 2022		F-5
Condensed Consolidated Statements of Shareholders’ Equity for the six months ended June 30, 2021 and 2022		F-7
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2021 and 2022		F-9
Notes to the Consolidated Financial Statements for the six months ended June 30, 2021 and 2022		F-11

F-1

BURNING ROCK BIOTECH LIMITED

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

		As of
	Notes	December 31, 2021		June 30, 2022
		RMB		RMB		US$
				(unaudited)
ASSETS
Current assets:
Cash and cash equivalents			1,431,317		1,148,597		171,481
Restricted cash			7,795		4,453		665
Short-term investments			63,757		—		—
Accounts receivable (net of allowances of RMB39,166 and RMB44,823 (US$6,692) as of December 31, 2021 and June 30, 2022, respectively.)	5		92,197		100,960		15,073
Contract assets	6		42,391		44,593		6,657
Inventories, net	7		123,210		129,637		19,355
Prepayments and other current assets	8		60,279		34,845		5,205
Total current assets			1,820,946		1,463,085		218,436
Non-current assets:
Equity method investment			910		733		109
Convertible note receivable			—		5,000		746
Property and equipment, net	9		325,438		301,249		44,975
Operating right-of-use-assets			81,007		66,655		9,951
Intangible assets, net			5,150		3,354		500
Other non-current assets			45,136		21,198		3,165
Total non-current assets			457,641		398,189		59,446
TOTAL ASSETS			2,278,587		1,861,274		277,882

F-2

BURNING ROCK BIOTECH LIMITED

CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

		As of
	Notes	December 31, 2021		June 30, 2022
		RMB		RMB		US$
				(unaudited)
LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ EQUITY
Current liabilities (including amounts of the consolidated VIE and its subsidiaries without recourse to the primary beneficiary of RMB279,601and RMB275,112 (US$41,072) as of December 31, 2021 and June 30, 2022, respectively):
Accounts payable			63,080		56,495		8,434
Deferred revenue			142,871		163,093		24,349
Accrued liabilities and other current liabilities			127,892		98,435		14,696
Customer deposits			972		1,052		157
Short-term borrowings			2,370		2,370		354
Current portion of operating lease liabilities			34,999		38,005		5,674
Total current liabilities			372,184		359,450		53,664
Non-current liabilities (including amounts of the consolidated VIE and its subsidiaries without recourse to the primary beneficiary of RMB38,232 and RMB41,896 (US$6,255) as of December 31, 2021 and June 30, 2022, respectively):
Other non-current liabilities			11,776		37,242		4,830
Operating lease liabilities			49,316		32,349		5,560
Total non-current liabilities			61,092		69,591		10,390
TOTAL LIABILITIES			433,276		429,041		64,054

F-3

BURNING ROCK BIOTECH LIMITED

CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

			As of
	Notes		December 31, 2021			June 30, 2022
			RMB			RMB			US$
						(unaudited)
Commitments and contingencies		15
Shareholders’ equity:
Class A ordinary shares (par value of US$0.0002 per share; 230,000,000 shares authorized; 87,784,001 shares and 88,116,172 shares issued and outstanding as of December 31, 2021 and June 30, 2022)				116			116			18
Class B ordinary shares (par value of US$0.0002 per share; 20,000,000 shares authorized; 17,324,848 shares issued and outstanding as of December 31, 2021 and June 30, 2022)				21			21			3
Equity forward		10		—			(66,850	)		(9,980	)
Additional paid-in capital				4,280,956			4,431,603			661,621
Accumulated deficits				(2,228,713	)		(2,752,238	)		(410,898	)
Accumulated other comprehensive loss				(207,069	)		(180,419	)		(26,936	)
Total shareholders’ equity				1,845,311			1,432,233			213,828
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY				2,278,587			1,861,274			277,882

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

F-4

BURNING ROCK BIOTECH LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

			For the six months ended June 30
	Notes		2021			2022
			RMB			RMB			US$
			(unaudited)			(unaudited)
Revenues:
Revenues from services				164,414			185,581			27,707
Revenues from sales of products				69,488			80,789			12,061
Total revenues		3		233,902			266,370			39,768
Cost of revenues:
Cost of services				(46,731	)		(66,462	)		(9,923	)
Cost of goods sold				(20,000	)		(29,726	)		(4,438	)
Total cost of revenues				(66,731	)		(96,188	)		(14,361	)
Gross profit				167,171			170,182			25,407
Operating expenses:
Research and development expenses				(185,485	)		(211,608	)		(31,592	)
Selling and marketing expenses				(123,188	)		(194,845	)		(29,090	)
General and administrative expenses (including related party amounts of RMB475 and RMB94 (US$14) for the six months ended June 30, 2021 and 2022, respectively.)		14		(232,389	)		(292,049	)		(43,602	)
Total operating expenses				(541,062	)		(698,502	)		(104,284	)
Loss from operations				(373,891	)		(528,320	)		(78,877	)
Interest income				1,468			4,517			674
Interest expenses				(1,075	)		90			13
Other expense, net (net off by related party income of RMB334 and nil for the six months ended June 30, 2021 and 2022, respectively.)				551			425			63
Foreign exchange (loss) gain, net				(503	)		(153	)		(23	)
Loss before income tax				(373,450	)		(523,441	)		(78,150	)

F-5

BURNING ROCK BIOTECH LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”), except for number of shares and per share data)

		For the six months ended June 30
	Notes	2021			2022
		RMB			RMB			US$
		(unaudited)			(unaudited)
Income tax expenses	12		(1,626	)		(84	)		(13	)
Net loss			(375,076	)		(523,525	)		(78,163	)
Net loss attributable to Burning Rock Biotech Limited’s shareholders			(375,076	)		(523,525	)		(78,163	)
Loss per share for class A and class B ordinary shares:	13
Class A ordinary shares - basic and diluted			(3.60	)		(4.98	)		(0.74	)
Class B ordinary shares - basic and diluted			(3.60	)		(4.98	)		(0.74	)
Weighted average shares outstanding used in loss per share computation:	13
Class A ordinary shares - basic and diluted			86,742,880			87,357,120			87,357,120
Class B ordinary shares - basic and diluted			17,324,848			17,324,848			17,324,848
Other comprehensive (loss) income, net of tax of nil:
Foreign currency translation adjustments			(20,900	)		26,650			3,979
Total comprehensive loss			(395,976	)		(496,875	)		(74,184	)
Total comprehensive loss attributable to Burning Rock Biotech Limited’s shareholders			(395,976	)		(496,875	)		(74,184	)

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

F-6

BURNING ROCK BIOTECH LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”), except for number of shares and per share data)

	Ordinary shares					Treasury stock			Additional paid- in capital			Accumulated deficit			Accumulated other comprehensive (loss) income			Total shareholders’ equity
	Number of shares			Amount
				RMB		RMB			RMB			RMB			RMB			RMB
Balance as of January 1, 2021		104,781,929			137		—			4,006,616			(1,418,160	)		(167,589	)		2,421,004
Net loss		—			—		—			—			(375,076	)		—			(375,076	)
Other comprehensive income		—			—		—			—			—			(20,900	)		(20,900	)
Issuance of restricted shares		2,424			—		—			—			—			—			—
Refund for prepaid subscription for forfeited restricted shares		(16,233	)		—		—			(1,629	)		—			—			(1,629	)
Purchase of treasury stock		(61,026	)		—		(4,270	)		—			—			—			(4,270	)
Exercise of options (note 11)		85,903			—		—			—			—			—			—
Adoption of ASC 326		—			—		—			—			(13,856	)		—			(13,856	)
Share-based compensation (note 11)		—			—		—			168,167			—			—			168,167
Balance as of June 30, 2021 (unaudited)		104,792,997			137		(4,270	)		4,173,154			(1,807,092	)		(188,489	)		2,173,440

F-7

BURNING ROCK BIOTECH LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”), except for number of shares and per share data)

	Ordinary shares					Treasury stock			Additional paid-in capital			Accumulated deficit						Accumulated other comprehensive (loss) income			Total shareholders’ equity
	Number of shares			Amount											Equity forward
				RMB		RMB			RMB			RMB			RMB			RMB			RMB
Balance as of January 1, 2022		105,108,849			137		—			4,280,956			(2,228,713	)		—			(207,069	)		1,845,311
Net loss		—			—		—			—			(523,525	)		—			—			(523,525	)
Other comprehensive income		—			—		—			—			—			—			26,650			26,650
Refund of consideration for Employee Share Incentive Program		(73,489	)		—		—			(3,385	)		—			—			—			(3,385	)
Purchase of treasury stock		—			—		(3,258	)		—			—			—			—			(3,258	)
Equity forward contract (note 10)		—			—		—			—			—			(66,850	)		—			(66,850	)
Exercise of options (note 11)		405,661			—		3,258			(3,258	)		—			—			—			—
Share-based compensation (note 11)		—			—		—			157,290			—			—			—			157,290
Balance as of June 30, 2022 (unaudited)		105,441,021			137		—			4,431,603			(2,752,238	)		(66,850	)		(180,419	)		1,432,233
Balance as of June 30, 2022 (US$) (unaudited)		105,441,021			21		—			661,621			(410,898	)		(9,980	)		(26,936	)		213,828

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

F-8

BURNING ROCK BIOTECH LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

	For the six months ended June 30
	2021			2022
	RMB			RMB			US$
	(unaudited)			(unaudited)
Cash flows from operating activities:
Net loss		(375,076	)		(523,525	)		(78,163	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		21,652			60,154			8,981
Allowance for credit losses		3,054			16,677			2,490
Inventory write down		1,697			7,007			1,046
Loss on disposal of equipment		13			1,113			166
Share of loss from equity method investee		143			217			32
Share-based compensation		168,167			157,290			23,483
Non-cash operating lease expenses		12,756			19,739			2,947
Derecognition of right of use assets and lease liability		—			(137	)		(20	)
Changes in operating assets and liabilities:
Inventories		(55,299	)		(10,948	)		(1,634	)
Accounts receivable		(344	)		(14,420	)		(2,153	)
Contract assets		(12,282	)		(13,317	)		(1,988	)
Prepayments and other current assets		(22,461	)		25,554			3,815
Amounts due from related parties		(416	)		—			—
Other non-current assets		—			24,187			3,611
Accounts payable		9,315			3,877			579
Deferred revenue		27,115			20,222			3,019
Accrued liabilities and other current liabilities		(1,305	)		(29,457	)		(4,399	)
Customer deposits		(78	)		80			12
Deferred government grants		(263	)		—			—
Operating lease liabilities		(8,531	)		(19,584	)		(2,924	)
Other non-current liabilities		—			21,637			3,230
Net cash used in operating activities		(232,143	)		(253,634	)		(37,870	)
Cash flows from investing activities:
Proceeds from maturity of short-term investments		323,335			65,598			9,794
Proceeds from disposal of equipment		2,559			352			53
Prepayment for property and equipment		—			(7,901	)		(1,180	)
Purchase of property and equipment		(104,822	)		(35,137	)		(5,243	)
Purchase of intangible assets		(320	)		(194	)		(29	)
Investment in convertible loan		—			(5,000	)		(746	)
Net cash generated from investing activities		220,752			17,718			2,649

F-9

BURNING ROCK BIOTECH LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

	For the six months ended June 30
	2021			2022
	RMB			RMB			US$
	(unaudited)			(unaudited)
Cash flows from financing activities:
Purchase of equity forward		—			(66,850	)		(9,980	)
Purchase of treasury shares		(4,270	)		(3,258	)		(486	)
Refund of consideration for Employee Share Incentive Program		(1,629	)		(3,385	)		(505	)
Finance lease payments		(2,647	)		—			—
Repayment of long-term borrowings		(4,577	)		—			—
Net cash used in financing activities		(13,123	)		(73,493	)		(10,971	)
Effect of exchange rate on cash, cash equivalents and restricted cash		(17,427	)		23,347			3,484
Net decrease in cash, cash equivalents and restricted cash		(41,941	)		(286,062	)		(42,708	)
Cash, cash equivalents and restricted cash at the beginning of period		1,925,206			1,439,112			214,854
Cash, cash equivalents and restricted cash at the end of period		1,883,265			1,153,050			172,146
Supplemental disclosures of non-cash information:
Purchase of property and equipment included in accounts payable		3,186			10,462			1,562
Purchase of property and equipment included in other non-current assets		(4,170	)		7,794			1,164
Derecognition of right-of-use asset and lease liability		—			137			20
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents		1,852,927			1,148,597			171,481
Restricted cash		30,338			4,453			665
Total cash, cash equivalents and restricted cash shown in the condensed consolidated balance sheets		1,883,265			1,153,050			172,146

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

F-10

BURNING ROCK BIOTECH LIMITED

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

1. ORGANIZATION

Burning Rock Biotech Limited (the “Company”) is a limited liability company incorporated in the Cayman Islands on March 10, 2014. The Company does not conduct any substantive operations on its own but instead conducts its business operations through its subsidiaries, the variable interest entity (“VIE”) and subsidiaries of the VIE. The Company, together with its subsidiaries, the VIE and the VIE’s subsidiaries (collectively, the “Group”) are principally engaged in developing and providing cancer therapy selection tests in the People’s Republic of China (the “PRC” or “China”).

There was no change to the Company’s principal subsidiaries, the VIE and the VIE’s subsidiaries since December 31, 2021.

To comply with PRC laws and regulations which prohibit and restrict foreign ownership of business involving the development and application of genomic diagnosis and treatment technology, the Group conducts its business in the PRC principally through the VIE and the VIE’s subsidiaries. The equity interests of the VIE are legally held by PRC shareholders (the “Nominee Shareholders”).

Despite the lack of majority ownership, the Company through the wholly foreign owned entity (“the WFOE”) has effective control of the VIE through a series of contractual arrangements (the “VIE agreements”) and a parent-subsidiary relationship exists between the Company and the VIE. Through the VIE agreements, the Nominee Shareholders of the VIE effectively assigned all of their voting rights underlying their equity interests in the VIE to the Company, and therefore, the Company has the power to direct the activities of the VIE that most significantly impact its economic performance. The Company also has the right to receive economic benefits that potentially could be significant to the VIE. The WFOE was the primary beneficiary of the VIE through October 2019 and the Company has replaced the WFOE as the primary beneficiary of the VIE since October 2019. Based on the above, the Company consolidates the VIE in accordance with SEC Regulation S-X-3A-02 and Accounting Standards Codification (“ASC”) Topic 810-10 (“ASC 810-10”), Consolidation: Overall.

F-11

BURNING ROCK BIOTECH LIMITED

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

1 ORGANIZATION (CONTINUED)

The following table sets forth the assets and liabilities of the VIE and subsidiaries of the VIE included in the Group’s unaudited interim condensed consolidated balance sheet:

	As of
	December 31, 2021		June 30, 2022
	RMB		RMB		US$
			(unaudited)
Cash and cash equivalents		185,850		332,367		49,621
Restricted cash		—		2,892		432
Accounts receivable (net of allowances of RMB38,922 and RMB44,566 (US$6,654) as of December 31, 2021 and June 30, 2022, respectively)		92,197		100,960		15,072
Contract assets		42,391		44,593		6,657
Inter-company receivables*		75,560		214,874		32,080
Inventories		119,257		120,952		18,058
Prepayments and other current assets		40,957		17,388		2,596
Total current assets		556,212		834,026		124,516
Property and equipment, net		42,623		58,285		8,702
Intangible assets, net		633		375		56
Other non-current assets		8,346		10,227		1,527
Operating right-of-use assets		51,630		41,875		6,252
Total non-current assets		103,232		110,762		16,537
TOTAL ASSETS		659,444		944,788		141,053
Accounts payable		27,102		19,925		2,975
Deferred revenue		133,489		163,095		24,349
Inter-company payables*		897,633		1,397,180		208,593
Accrued liabilities and other current liabilities		89,976		62,557		9,339
Customer deposits		972		484		72
Short-term borrowing		2,370		2,370		354
Current portion of operating lease liabilities		25,692		26,681		3,983
Total current liabilities		1,177,234		1,672,292		249,665
Deferred government grant
Other non-current liabilities		8,563		24,034		3,588
Non-current portion of operating lease liabilities		29,669		17,862		2,667
Total non-current liabilities		38,232		41,896		6,255
TOTAL LIABILITIES		1,215,466		1,714,188		255,920

* Inter-company receivables/payables represent balances of the VIE and subsidiaries of the VIE due from/to the Company and the Group’s consolidated subsidiaries.

F-12

BURNING ROCK BIOTECH LIMITED

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

1 ORGANIZATION (CONTINUED)

As of December 31, 2021, and June 30, 2022, there were no pledges or collateralization of the VIE and VIE’s subsidiaries’ assets that can only be used to settle obligations of the VIE and VIEs’ subsidiaries. The amounts of the net liabilities of the VIE and subsidiaries of the VIE were RMB556,022 and RMB769,398 (US$114,871) as of December 31, 2021, and June 30, 2022, respectively. The creditors of the VIE and subsidiaries of the VIE’s third-party liabilities did not have recourse to the general credit of the primary beneficiary in the normal course of business. The VIE holds certain assets, including detection equipment and related equipment for use in their operations. The Company did not provide nor intend to provide additional financial or other support not previously contractually required to the VIE and subsidiaries of the VIE during the periods presented.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission regarding financial reporting that are consistent with those used in the preparation of the Company’s audited consolidated financial statements for the year ended December 31, 2021. Accordingly, these unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by U.S. GAAP for annual financial statements.

The unaudited interim condensed financial statements have been prepared on the same basis as the audited consolidated financial statements for the year ended December 31, 2021 and, in the opinion of management, reflect all normal recurring adjustments, necessary to present a fair statement of the results for the interim periods presented. Results of the operations for the six months ended June 30, 2022 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2021.

The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.

Convenience translation

Translations of amounts from RMB into US$ for the convenience of the reader have been calculated at the exchange rate of RMB 6.6981 per US$1.00 on June 30, 2022, as published on the website of the United States Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at such rate or at any other rate.

F-13

BURNING ROCK BIOTECH LIMITED

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Use of estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affected the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Areas where management uses subjective judgment include, but are not limited to, allowance for credit losses, inventory provision, standalone selling prices of performance obligations, the useful lives and impairment of long-lived assets, breakage income and incremental borrowing rates for lease liabilities. Management bases its estimates on historical experience and on assumptions that it believes are reasonable. Actual results could differ materially from those estimates.

Accounts receivable, contract assets and allowance for credit losses

The Group records the allowance for credit losses as an offset to accounts receivable and contract assets, with estimated credit losses charged to “General and administrative expenses” in the condensed consolidated statements of comprehensive loss. The Group assesses credit loss by reviewing accounts receivable and contract assets on a collective basis where similar characteristics exist, primarily based on similar business segments, service or product offerings and on an individual basis when the Group identifies specific customers with known disputes or collectability issues. The Group applies a migration roll rate method that considers historical collectability based on past due status, the age of the accounts receivable and contract asset balances, credit quality of the Group’s customers based on ongoing credit evaluations, current economic conditions, reasonable and supportable forecasts of future economic conditions and other factors that may affect the Group’s ability to collect from customers. The Group writes off accounts receivable and contract assets are deemed uncollectible when after all collection efforts have ceased.

F-14

BURNING ROCK BIOTECH LIMITED

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Contract liabilities

The Group records a contract liability, which is presented as “deferred revenue” on the consolidated balance sheets when a customer pays consideration before the Group provides products or services.

Deferred revenue increased RMB20,222 (US$3,019) compared to the year ended December 31, 2021 is a result of the increase in consideration received from the Group’s customers. The Group receives payments from customers based on a billing schedule as established in contracts. Revenue recognized that was included in deferred revenue balance at the beginning of the period was RMB18,845 and RMB14,101(US$2,105) for the six months ended June 30, 2021 and 2022, respectively.

The transaction prices allocated to the remaining performance obligations (unsatisfied or partially satisfied) as of December 31, 2021 and June 30, 2022 were RMB199,354 and RMB 356,887(US$53,282), respectively. RMB203,955 (US$30,450) of transaction prices allocated to the remaining performance obligations which are expected to be recognized as revenue after one year are related to pharma research and development services. All the other amounts of transaction prices allocated to the remaining performance obligations are expected to be recognized as revenue within one year. The amounts disclosed above do not include variable consideration which is constrained.

Significant accounting policies

For a more complete discussion of the Company’s significant accounting policies and other information, the unaudited interim condensed consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report (Form 20-F) for the year ended December 31, 2021.

There have been no material changes to the Company’s significant accounting policies as of and for the six months ended June 30, 2022, as compared to the significant accounting policies described in the Annual Report.

F-15

BURNING ROCK BIOTECH LIMITED

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

3 SEGMENT REPORTING

The Group had three operating segments, including the central laboratory business, the in-hospital business and pharma research and development services for the six-months ended June 30, 2022 and 2021. The operating segments also represented the reporting segments. The Group’s CODM assesses the performance of the operating segments based on the measures of revenues, cost of revenue and gross profit by the central laboratory business, the in-hospital business and pharma research and development services. Other than the information provided below, the CODM does not use any other measures by segments.

Summarized information by segments for the six months ended June 30, 2022 and 2021 is as follows:

	For the six months ended June 30,2021												For the six months ended June 30,2022
	Central laboratory business			In-hospital business			Pharma research and development services			Total			Central laboratory business			In-hospital business			Pharma research and development services			Total
	RMB			RMB			RMB			RMB			RMB			RMB			RMB			RMB			US$
	(unaudited)			(unaudited)			(unaudited)			(unaudited)			(unaudited)			(unaudited)			(unaudited)			(unaudited)			(unaudited)
Revenues:
Revenues from services		154,560			8			9,846			164,414			152,808			2,345			30,428			185,581			27,707
Revenues from sales of products		—			69,488			—			69,488			—			80,789			—			80,789			12,061
Total revenues		154,560			69,496			9,846			233,902			152,808			83,134			30,428			266,370			39,768
Cost of revenues		(40,667	)		(20,000	)		(6,064	)		(66,731	)		(44,659	)		(29,726	)		(21,803	)		(96,188	)		(14,361	)
Gross profit		113,893			49,496			3,782			167,171			108,149			53,408			8,625			170,182			25,407

F-16

BURNING ROCK BIOTECH LIMITED

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

4 FAIR VALUE MEASUREMENTS

The Group applies ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2—Includes other inputs that are directly or indirectly observable in the marketplace.

Level 3—Unobservable inputs which are supported by little or no market activity.

ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach; and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.

The carrying amounts of cash and cash equivalent, restricted cash, short-term investments, accounts receivable, amounts due from and due to related parties, accounts payable and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amounts of long-term borrowings and lease liabilities approximate their fair values since they bear interest at rates which approximate market interest rates.

The Group did not transfer any assets or liabilities in or out of Level 3 during the six months ended June 30, 2021 and 2022. As of December 31, 2021 and June 30, 2022, there was no warrants outstanding. Therefore, there was no asset or liability measured at fair value using Level 3 unobservable inputs on a recurring basis as of December 31, 2021 and June 30, 2022.

There were no financial assets and liabilities measured and recorded at fair value on a non-recurring basis as of December 31, 2021 and June 30, 2022.

F-17

BURNING ROCK BIOTECH LIMITED

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

5 ACCOUNTS RECEIVABLE, NET

	As of
	December 31, 2021			June 30, 2022
	RMB			RMB			US$
				(unaudited)
Accounts receivable		131,363			145,783			21,765
Allowance for credit losses		(39,166	)		(44,823	)		(6,692	)
		92,197			100,960			15,073

The changes in the allowance for credit losses were as follows:

	For the six months ended June 30
	2021			2022
	RMB			RMB		US$
	(unaudited)			(unaudited)
Balance at beginning of the period		24,215			39,166		5,847
Adoption of ASC 326		11,358			—		—
Provisions		(937	)		5,657		845
Balance at end of the period		34,636			44,823		6,692

6 CONTRACT ASSETS

	As of
	December 31, 2021			June 30, 2022
	RMB			RMB			US$
				(unaudited)
Contract assets		56,869			70,186			10,478
Allowance for credit losses		(14,478	)		(25,593	)		(3,821	)
		42,391			44,593			6,657

F-18

BURNING ROCK BIOTECH LIMITED

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

6 CONTRACT ASSETS (CONTINUED)

The changes in the allowance for credit losses were as follows:

	For the six months ended June 30
	2021		2022
	RMB		RMB		US$
			(unaudited)
Balance at beginning of the period		3,497		14,478		2,162
Adoption of ASC 326		2,383		—		—
Provisions		4,088		11,115		1,659
Balance at end of the period		9,968		25,593		3,821

7 INVENTORIES, NET

	As of
	December 31, 2021			June 30, 2022
	RMB			RMB			US$
				(unaudited)
Raw materials		82,455			90,957			13,580
Work in progress		7,902			10,220			1,526
Finished goods		35,481			38,095			5,687
Inventory provision		(2,628	)		(9,635	)		(1,438	)
		123,210			129,637			19,355

8 PREPAYMENTS AND OTHER CURRENT ASSETS

	As of
	December 31, 2021		June 30, 2022
	RMB		RMB		US$
			(unaudited)
Deductible input VAT		23,232		17,828		2,663
Prepayments		30,695		10,746		1,605
Advance to employees		—		1,673		250
Deposits		1,874		2,158		322
Interest receivables		111		405		60
Employee loan (i)		3,500		—		—
Others (ii)		867		2,035		305
		60,279		34,845		5,205

(i) On March 16, 2021 the Group extended a loan to an employee with principal amount of RMB3,500 (US$523) at simple annual interest rate of 3.08%. The loan was repaid in February 2022.

(ii) Certain financial assets included in others, net of the allowance for credit losses of RMB95 and nil as of December 31, 2021 and June 30, 2022, respectively. Cumulative effect of adopting ASC 326 on January 1, 2021 of other current assets was RMB115 (US$17). Reversal of provision were RMB97 and RMB95 (US$14) for the six months ended June 30, 2021 and 2022, respectively.

F-19

BURNING ROCK BIOTECH LIMITED

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

9 PROPERTY AND EQUIPMENT, NET

Property and equipment consist of the following:

	As of
	December 31, 2021			June 30, 2022
	RMB			RMB			US$
				(unaudited)
Machinery and laboratory equipment		231,289			246,389			36,785
Vehicles		2,812			2,808			419
Furniture and tools		15,723			16,756			2,502
Electronic equipment		48,068			49,937			7,455
Leasehold improvements		161,037			161,691			24,140
Construction in progress		27,555			40,062			5,981
		486,484			517,643			77,282
Accumulated depreciation		(161,046	)		(216,394	)		(32,307	)
		325,438			301,249			44,975

Depreciation expenses recognized for the six months ended June 30, 2021 and 2022 were RMB20,614, and RMB57,953 (US$8,652), respectively. 

F-20

BURNING ROCK BIOTECH LIMITED

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

10 EQUITY FORWARD

On June 21, 2022, the Company’s board of directors authorized a share repurchase plan under which the Company may repurchase up to US$10,000 its Class A ordinary shares in the form of its ADS during a 12-month period (the “Share Repurchase Program”). The Company entered an accelerated share repurchase (“ASR”) agreement with Bank of America, pursuant to which it prepaid US$10,000 with the repurchase price determined by the volume-weighted average price (“VWAP”) of the Company’s ADS over the term of the ASR. The settlement date of this contract was August 23, 2022.

The Company evaluated and concluded the ASR agreement was an equity classified forward contract pursuant to ASC 815-40-25-10 and recognized the contract notional amount as contra-equity in the statement of changes in shareholder equity for the six months ended June 30, 2022

11 SHARE-BASED COMPENSATION

Total share-based compensation expenses recognized for the six months ended June 30, 2021 and 2022 were as follows:

	For the six months ended June 30,
	2021		2022
	RMB		RMB		US$
	(unaudited)		(unaudited)
Cost of revenues		745		806		120
Research and development expenses		43,230		24,222		3,616
Selling and marketing expenses		5,442		3,932		587
General and administrative expenses		118,750		128,330		19,159
		168,167		157,290		23,483

F-21

BURNING ROCK BIOTECH LIMITED

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

12 INCOME TAXES

For interim income tax reporting, the Group computed an estimate annual effective tax rate (“EAETR”) and apply it to year-to-date ordinary income (loss), exclusive of discrete items. Tax jurisdictions with a projected or year-to-date loss for which a tax benefit cannot be realized are excluded. The tax effects of unusual or infrequently occurring items, including changes in judgment about valuation allowances and effects of changes in tax laws or rates, are reported in the interim period in which they occur.

The Group recorded income tax expenses of RMB84 (US$13), representing effective tax rate of nil for the six months ended June 30, 2022 compared to RMB1,626 for the six months ended June 30, 2021. The primary difference between the PRC statutory tax rate of 15% for qualified high-tech enterprise and the effective tax rate for the six months ended June 30, 2022 are primarily due to permanent book to tax adjustments such as super R&D deduction netted with nondeductible entertainment expense and stock compensation expense.

As of June 30, 2022, there was no significant impact from tax uncertainties on the Group’s unaudited interim condensed consolidated financial statements. The Group did not record any interest and penalties related to an uncertain tax position for the six months ended June 30, 2021 and 2022. The Group does not expect the amount of unrecognized tax benefits would increase significantly in the next 12 months.

In general, the PRC tax authorities have up to five years to conduct examinations of the tax filings of the Company’s PRC subsidiaries, the VIE and the VIE’s subsidiaries. Accordingly, the PRC tax filings from 2017 through 2021 remain open to examination by the respective tax authorities. The Group may also be subject to the examinations of the tax filings in other jurisdictions, which are not material to the consolidated financial statements.

F-22

BURNING ROCK BIOTECH LIMITED

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

13 LOSS PER SHARE

Basic and diluted loss per share for the six months ended June 30, 2021 and 2022 are calculated as follows:

	For the six months ended June 30,
	2021						2022
	Class A			Class B			Class A						Class B
	RMB			RMB			RMB			US$			RMB			US$
	(unaudited)						(unaudited)
Numerator:
Net loss attributable to ordinary shareholders		(312,635	)		(62,441	)		(436,882	)		(65,227	)		(86,643	)		(12,936	)
Denominator:
Weighted-average number of ordinary shares outstanding		87,470,332			17,324,848			87,909,137			87,909,137			17,324,848			17,324,848
Effect of unvested restricted shares		(727,452	)		—			(552,017	)		(552,017	)		—			—
Weighted average number of ordinary shares outstanding – basic and diluted		86,742,880			17,324,848			87,357,120			87,357,120			17,324,848			17,324,848
Loss per share - basic and diluted		(3.60	)		(3.60	)		(4.98	)		(0.74	)		(4.98	)		(0.74	)

For the six months ended June 30, 2021 and 2022, the two-class method was applied to the outstanding Class A and Class B ordinary shares. The unvested restricted shares were excluded from the computation of weighted-average number or ordinary shares outstanding because the Group is in a loss position and the holders of the restricted shares do not have an obligation to fund losses of the Group. The effects of all outstanding share options were excluded from the computation of diluted loss per share for the six months ended June 30, 2021 and 2022 as their effects would be anti-dilutive.

F-23

BURNING ROCK BIOTECH LIMITED

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

14 RELATED PARTY TRANSACTIONS

a) Related parties

Name of related parties	Relationship
Yusheng Han	Shareholder of the shareholder of the Company, Chief Executive Officer and director
Shaokun Chuai	Shareholder of the shareholder of the Company, Chief Operating Officer and director
EaSuMed Holding Ltd.	Equity method investee
Guangzhou Burning Rock Biological Engineering Co., Ltd.	Company controlled by the Founder

b) The Group had the following related party balance at the end of the periods:

	As of
	December 31, 2021		June 30, 2022
	RMB		RMB		US$
			(unaudited)
EaSuMed Holding Ltd.		212		—		—
Total amounts due from related parties		212		—		—

All the balances with a related party as of December 31, 2021 were unsecured. All outstanding balances are repayable on demand unless otherwise disclosed. No allowance for credit losses was recognized for the amounts due from related parties for the six months ended June 30, 2021 and 2022.

F-24

BURNING ROCK BIOTECH LIMITED

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

14 RELATED PARTY TRANSACTIONS (CONTINUED)

c) The Group had the following related party transactions:

	For the six months ended June 30,
	2021		2022
	RMB		RMB		US$
	(unaudited)		(unaudited)
Consulting service received from:
EaSuMed Holding Ltd.		475		94		14
Rental income from:
Guangzhou Burning Rock Biological Engineering Co., Ltd.(i)		97		—		—
Equipment usage service income from:
Guangzhou Burning Rock Biological Engineering Co., Ltd.(ii)		237		—		—

(i) On April 1, 2021, the Group entered into a one-year sublease agreement on its office with a related party and recorded RMB97 in other income for the six month ended June 30, 2021. The lease was early terminated on September 30, 2021.

(ii) On April 1, 2021, the Group entered into a contract to provide equipment usage service to its related party with a total contact amount of RMB997, of which RMB237 was recorded in other income for the six month ended June 30, 2021. The contract was early terminated on September 30, 2021.

15 COMMITMENTS AND CONTINGENCIES

Capital expenditure commitments

The Group has capital expenditure commitments for the laboratory leasehold improvements of RMB6,520 (US$973) as of June 30, 2022, which are scheduled to be paid within one year.

Contingencies

The Group is currently not involved in any legal or administrative proceedings that may have a material adverse impact on the Group’s business, financial position or results of operations.

F-25

BURNING ROCK BIOTECH LIMITED

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Amounts in thousands of Renminbi (“RMB”) and US dollars (“US$”),

except for number of shares and per share data)

16 RESTRICTED NET ASSETS

Under the PRC laws and regulations, there are restrictions on the Company’s PRC subsidiaries and the VIE with respect to transferring certain of their net assets to the Company either in the form of dividends, loans, or advances. The Company’s restricted net assets from its PRC subsidiaries, the VIE and VIE’s subsidiaries, as determined pursuant to PRC GAAP, were RMB382,724 and RMB344,331 (US$51,407) as of December 31, 2021 and June 30, 2022, respectively.

17 SUBSEQUENT EVENTS

On August 23, 2022, the Company repurchased a total of 3,023,138 Class A ordinary shares in the form of ADSs upon settlement of the ASR program.

F-26

XML

Cover Page	6 Months Ended
	Jun. 30, 2022
Document Information [Line Items]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Registrant Name	BURNING ROCK BIOTECH LIMITED
Entity Central Index Key	0001792267
Current Fiscal Year End Date	--12-31
Entity File Number	001-39316

XML

Condensed Consolidated Balance Sheet ¥ in Thousands, $ in Thousands	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 CNY (¥)
Current assets:
Cash and cash equivalents	¥ 1,148,597	$ 171,481	¥ 1,431,317
Restricted cash	4,453	665	7,795
Short-term investments	0	0	63,757
Accounts receivable (net of allowances of RMB39,166 and RMB44,823 (US$6,692) as of December 31, 2021 and June 30, 2022, respectively.)	100,960	15,073	92,197
Contract assets	44,593	6,657	42,391
Inventories, net	129,637	19,355	123,210
Prepayments and other current assets	34,845	5,205	60,279
Total current assets	1,463,085	218,436	1,820,946
Non-current assets:
Equity method investment	733	109	910
Convertible note receivable, Noncurrent	5,000	746	0
Property and equipment, net	301,249	44,975	325,438
Operating right-of-use assets	66,655	9,951	81,007
Intangible assets, net	3,354	500	5,150
Other non-current assets	21,198	3,165	45,136
Total non-current assets	398,189	59,446	457,641
TOTAL ASSETS	1,861,274	277,882	2,278,587
Current liabilities (including amounts of the consolidated VIE and its subsidiaries without recourse to the primary beneficiary of RMB279,601and RMB275,112 (US$41,072) as of December 31, 2021 and June 30, 2022, respectively):
Accounts payable	56,495	8,434	63,080
Deferred revenue	163,093	24,349	142,871
Accrued liabilities and other current liabilities	98,435	14,696	127,892
Customer deposits	1,052	157	972
Short-term borrowings	2,370	354	2,370
Current portion of operating lease liabilities	38,005	5,674	34,999
Total current liabilities	359,450	53,664	372,184
Non-current liabilities (including amounts of the consolidated VIE and its subsidiaries without recourse to the primary beneficiary of RMB38,232 and RMB41,896 (US$6,255) as of December 31, 2021 and June 30, 2022, respectively):
Other non-current liabilities	37,242	4,830	11,776
Operating lease liabilities	32,349	5,560	49,316
Total non-current liabilities	69,591	10,390	61,092
TOTAL LIABILITIES	429,041	64,054	433,276
Commitments and contingencies
Shareholders' equity:
Equity forward	(66,850)	(9,980)	0
Additional paid-in capital	4,431,603	661,621	4,280,956
Accumulated deficits	(2,752,238)	(410,898)	(2,228,713)
Accumulated other comprehensive loss	(180,419)	(26,936)	(207,069)
Total shareholders' equity	1,432,233	213,828	1,845,311
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	1,861,274	277,882	2,278,587
Common Class A [Member]
Shareholders' equity:
Ordinary shares	116	18	116
Common Class B [Member]
Shareholders' equity:
Ordinary shares	¥ 21	$ 3	¥ 21

XML

Condensed Consolidated Balance Sheet (Parenthetical) ¥ in Thousands, $ in Thousands	Jun. 30, 2022 CNY (¥) shares	Jun. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 CNY (¥) shares	Dec. 31, 2021 $ / shares
Accounts Receivable, Allowance	¥ 44,823	$ 6,692	¥ 39,166
Common Class A [Member]
Ordinary Shares, Par value | $ / shares		$ 0.0002		$ 0.0002
Ordinary Shares, Shares authorized	230,000,000	230,000,000	230,000,000
Ordinary Shares, Shares issued	88,116,172	88,116,172	87,784,001
Ordinary Shares, Shares outstanding	88,116,172	88,116,172	87,784,001
Common Class B [Member]
Ordinary Shares, Par value | $ / shares		$ 0.0002		$ 0.0002
Ordinary Shares, Shares authorized	20,000,000	20,000,000	20,000,000
Ordinary Shares, Shares issued	17,324,848	17,324,848	17,324,848
Ordinary Shares, Shares outstanding	17,324,848	17,324,848	17,324,848
Nonrecourse [Member]
Consolidated VIE and its subsidiaries, Current	¥ 275,112	$ 41,072	¥ 279,601
Consolidated VIE and its subsidiaries, Non-current	¥ 41,896	$ 6,255	¥ 38,232

XML

Condensed Consolidated Statements Of Comprehensive Loss ¥ in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2022 CNY (¥) ¥ / shares shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 CNY (¥) ¥ / shares shares
Revenues:
Revenues	¥ 266,370	$ 39,768	¥ 233,902
Cost of revenues:
Cost of revenues:	(96,188)	(14,361)	(66,731)
Gross profit	170,182	25,407	167,171
Operating expenses:
Research and development expenses	(211,608)	(31,592)	(185,485)
Selling and marketing expenses	(194,845)	(29,090)	(123,188)
General and administrative expenses (including related party amounts of RMB475 and RMB94 (US$14) for the six months ended June 30, 2021 and 2022, respectively.)	(292,049)	(43,602)	(232,389)
Total operating expenses	(698,502)	(104,284)	(541,062)
Loss from operations	(528,320)	(78,877)	(373,891)
Interest income	4,517	674	1,468
Interest expense	90	13	(1,075)
Other expense, net (net off by related party income of RMB334 and nil for the six months ended June 30, 2021 and 2022, respectively.)	425	63	551
Foreign exchange (loss) gain, net	(153)	(23)	(503)
Loss before income tax	(523,441)	(78,150)	(373,450)
Income tax expenses	(84)	(13)	(1,626)
Net loss	(523,525)	(78,163)	(375,076)
Net loss attributable to Burning Rock Biotech Limited's shareholders	(523,525)	(78,163)	(375,076)
Other comprehensive (loss) income, net of tax of nil:
Foreign currency translation adjustments	26,650	3,979	(20,900)
Total comprehensive loss	(496,875)	(74,184)	(395,976)
Total comprehensive loss attributable to Burning Rock Biotech Limited's shareholders	¥ (496,875)	$ (74,184)	¥ (395,976)
Common Class A [Member]
Loss per share for class A and class B ordinary shares:
Loss per share - basic | (per share)	¥ (4.98)	$ (0.74)	¥ (3.6)
Loss per share - diluted | (per share)	¥ (4.98)	$ (0.74)	¥ (3.6)
Weighted average shares outstanding used in loss per share computation:
Weighted average shares outstanding used in loss per share - basic	87,357,120	87,357,120	86,742,880
Weighted average shares outstanding used in loss per share - diluted	87,357,120	87,357,120	86,742,880
Common Class B [Member]
Loss per share for class A and class B ordinary shares:
Loss per share - basic | (per share)	¥ (4.98)	$ (0.74)	¥ (3.6)
Loss per share - diluted | (per share)	¥ (4.98)	$ (0.74)	¥ (3.6)
Weighted average shares outstanding used in loss per share computation:
Weighted average shares outstanding used in loss per share - basic	17,324,848	17,324,848	17,324,848
Weighted average shares outstanding used in loss per share - diluted	17,324,848	17,324,848	17,324,848
Service [Member]
Revenues:
Revenues	¥ 185,581	$ 27,707	¥ 164,414
Cost of revenues:
Cost of revenues:	(66,462)	(9,923)	(46,731)
Product [Member]
Revenues:
Revenues	80,789	12,061	69,488
Cost of revenues:
Cost of revenues:	¥ (29,726)	$ (4,438)	¥ (20,000)

XML

Condensed Consolidated Statements Of Comprehensive Loss (Parenthetical) ¥ in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)
Related Party Income			¥ 334
General and Administrative Expense [Member]
Expense related to related parties	¥ 94	$ 14	¥ 475

XML

Condensed Consolidated Statements Of Shareholders' Equity ¥ in Thousands, $ in Thousands	CNY (¥)	USD ($)	Common Stock [Member] CNY (¥) shares	Common Stock [Member] USD ($) shares	Treasury stock [Member] CNY (¥)	Treasury stock [Member] USD ($)	Additional paid-in capital [Member] CNY (¥)	Additional paid-in capital [Member] USD ($)	Accumulated deficits [Member] CNY (¥)	Accumulated deficits [Member] USD ($)	Equity forward [Member] CNY (¥)	Equity forward [Member] USD ($)	Accumulated other comprehensive (loss) income [Member] CNY (¥)	Accumulated other comprehensive (loss) income [Member] USD ($)
Beginning balance at Dec. 31, 2020	¥ 2,421,004		¥ 137				¥ 4,006,616		¥ (1,418,160)				¥ (167,589)
Beginning balance, (in shares) at Dec. 31, 2020 | shares			104,781,929	104,781,929
Net loss	(375,076)								(375,076)
Other comprehensive income	(20,900)												(20,900)
Issuance of restricted shares (note 14) | shares			2,424	2,424
Refund for prepaid subscription for forfeited restricted shares	(1,629)						(1,629)
Refund for prepaid subscription for forfeited restricted shares (in shares) | shares			(16,233)	(16,233)
Adoption of ASC 326	(13,856)								(13,856)
Purchase of treasury stock	(4,270)				¥ (4,270)
Purchase of treasury stock (in shares) | shares			(61,026)	(61,026)
Exercise of options (note 11) (in shares) | shares			85,903	85,903
Share-based compensation (note 11)	168,167						168,167
Ending balance, (in shares) at Jun. 30, 2021 | shares			104,792,997	104,792,997
Ending balance at Jun. 30, 2021	2,173,440		¥ 137		(4,270)		4,173,154		(1,807,092)				(188,489)
Beginning balance at Dec. 31, 2021	1,845,311		¥ 137				4,280,956		(2,228,713)				(207,069)
Beginning balance, (in shares) at Dec. 31, 2021 | shares			105,108,849	105,108,849
Net loss	(523,525)	$ (78,163)							(523,525)
Other comprehensive income	26,650												26,650
Refund of consideration for Employee Share Incentive Program	(3,385)						(3,385)
Refund of consideration for Employee Share Incentive Program, (in shares) | shares			(73,489)	(73,489)
Purchase of treasury stock	(3,258)				(3,258)
Equity forward contract (note 10)	(66,850)										¥ (66,850)
Exercise of options (note 11)					3,258		(3,258)
Exercise of options (note 11) (in shares) | shares			405,661	405,661
Share-based compensation (note 11)	157,290						157,290
Ending balance, (in shares) at Jun. 30, 2022 | shares			105,441,021	105,441,021
Ending balance at Jun. 30, 2022	¥ 1,432,233	$ 213,828	¥ 137	$ 21	¥ 0	$ 0	¥ 4,431,603	$ 661,621	¥ (2,752,238)	$ (410,898)	¥ (66,850)	$ (9,980)	¥ (180,419)	$ (26,936)

XML

Consolidated Statements Of Cash Flows ¥ in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)
Cash flows from operating activities:
Net loss	¥ (523,525)	$ (78,163)	¥ (375,076)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	60,154	8,981	21,652
Allowance for credit losses	16,677	2,490	3,054
Inventory write down	7,007	1,046	1,697
Loss on disposal of equipment	1,113	166	13
Share of loss from equity method investee	217	32	143
Share-based compensation	157,290	23,483	168,167
Non-cash operating lease expenses	19,739	2,947	12,756
Derecognition of right of use assets and lease liability	(137)	(20)	0
Changes in operating assets and liabilities:
Inventories	(10,948)	(1,634)	(55,299)
Accounts receivable	(14,420)	(2,153)	(344)
Contract assets	(13,317)	(1,988)	(12,282)
Prepayments and other current assets	25,554	3,815	(22,461)
Amounts due from related parties	0	0	(416)
Other non-current assets	24,187	3,611	0
Accounts payable	3,877	579	9,315
Deferred revenue	20,222	3,019	27,115
Accrued liabilities and other current liabilities	(29,457)	(4,399)	(1,305)
Customer deposits	80	12	(78)
Deferred government grants	0	0	(263)
Operating lease liabilities	(19,584)	(2,924)	(8,531)
Other non-current liabilities	21,637	3,230	0
Net cash used in operating activities	(253,634)	(37,870)	(232,143)
Cash flows from investing activities:
Proceeds from maturity of short-term investments	65,598	9,794	323,335
Proceeds from disposal of equipment	352	53	2,559
Prepayment for property and equipment	(7,901)	(1,180)	0
Purchase of property and equipment	(35,137)	(5,243)	(104,822)
Purchase of intangible assets	(194)	(29)	(320)
Investment in convertible loan	(5,000)	(746)	0
Net cash generated from investing activities	17,718	2,649	220,752
Cash flows from financing activities:
Purchase of equity forward	(66,850)	(9,980)	0
Purchase of treasury shares	(3,258)	(486)	(4,270)
Refund of consideration for Employee Share Incentive Program	(3,385)	(505)	(1,629)
Finance lease payments	0	0	(2,647)
Repayment of long-term borrowings	0		(4,577)
Net cash used in financing activities	(73,493)	(10,971)	(13,123)
Effect of exchange rate on cash, cash equivalents and restricted cash	23,347	3,484	(17,427)
Net decrease in cash, cash equivalents and restricted cash	(286,062)	(42,708)	(41,941)
Cash, cash equivalents and restricted cash at the beginning of period	1,439,112	214,854	1,925,206
Total cash, cash equivalents and restricted cash shown in the condensed consolidated balance sheets	1,153,050	172,146	1,883,265
Supplemental disclosures of non-cash information:
Purchase of property and equipment included in accounts payable	10,462	1,562	3,186
Purchase of property and equipment included in other non-current assets	7,794	1,164	(4,170)
Derecognition of right-of-use asset and lease liability	137	20	0
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	1,148,597	171,481	1,852,927
Restricted cash	4,453	665	30,338
Total cash, cash equivalents and restricted cash shown in the condensed consolidated balance sheets	¥ 1,153,050	$ 172,146	¥ 1,883,265

XML

Organization

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

1. ORGANIZATION

Burning Rock Biotech Limited (the “Company”) is a limited liability company incorporated in the Cayman Islands on March 10, 2014. The Company does not conduct any substantive operations on its own but instead conducts its business operations through its subsidiaries, the variable interest entity (“VIE”) and subsidiaries of the VIE. The Company, together with its subsidiaries, the VIE and the VIE’s subsidiaries (collectively, the “Group”) are principally engaged in developing and providing cancer therapy selection tests in the People’s Republic of China (the “PRC” or “China”).

There was no change to the Company’s principal subsidiaries, the VIE and the VIE’s subsidiaries since December 31, 2021.

To comply with PRC laws and regulations which prohibit and restrict foreign ownership of business involving the development and application of genomic diagnosis and treatment technology, the Group conducts its business in the PRC principally through the VIE and the VIE’s subsidiaries. The equity interests of the VIE are legally held by PRC shareholders (the “Nominee Shareholders”).

Despite the lack of majority ownership, the Company through the wholly foreign owned entity (“the WFOE”) has effective control of the VIE through a series of contractual arrangements (the “VIE agreements”) and a parent-subsidiary relationship exists between the Company and the VIE. Through the VIE agreements, the Nominee Shareholders of the VIE effectively assigned all of their voting rights underlying their equity interests in the VIE to the Company, and therefore, the Company has the power to direct the activities of the VIE that most significantly impact its economic performance. The Company also has the right to receive economic benefits that potentially could be significant to the VIE. The WFOE was the primary beneficiary of the VIE through October 2019 and the Company has replaced the WFOE as the primary beneficiary of the VIE since October 2019. Based on the above, the Company consolidates the VIE in accordance with SEC Regulation S-X-3A-02 and Accounting Standards Codification (“ASC”) Topic 810-10 (“ASC 810-10”), Consolidation: Overall.

The following table sets forth the assets and liabilities of the VIE and subsidiaries of the VIE included in the Group’s unaudited interim condensed consolidated balance sheet:

	As of
	December 31, 2021		June 30, 2022
	RMB		RMB		US$
			(unaudited)
Cash and cash equivalents		185,850		332,367		49,621
Restricted cash		—		2,892		432
Accounts receivable (net of allowances of RMB38,922 and RMB44,566 (US$6,654) as of December 31, 2021 and June 30, 2022, respectively)		92,197		100,960		15,072
Contract assets		42,391		44,593		6,657
Inter-company receivables*		75,560		214,874		32,080
Inventories		119,257		120,952		18,058
Prepayments and other current assets		40,957		17,388		2,596
Total current assets		556,212		834,026		124,516
Property and equipment, net		42,623		58,285		8,702
Intangible assets, net		633		375		56
Other non-current assets		8,346		10,227		1,527
Operating right-of-use assets		51,630		41,875		6,252
Total non-current assets		103,232		110,762		16,537
TOTAL ASSETS		659,444		944,788		141,053
Accounts payable		27,102		19,925		2,975
Deferred revenue		133,489		163,095		24,349
Inter-company payables*		897,633		1,397,180		208,593
Accrued liabilities and other current liabilities		89,976		62,557		9,339
Customer deposits		972		484		72
Short-term borrowing		2,370		2,370		354
Current portion of operating lease liabilities		25,692		26,681		3,983
Total current liabilities		1,177,234		1,672,292		249,665
Deferred government grant
Other non-current liabilities		8,563		24,034		3,588
Non-current portion of operating lease liabilities		29,669		17,862		2,667
Total non-current liabilities		38,232		41,896		6,255
TOTAL LIABILITIES		1,215,466		1,714,188		255,920

* Inter-company receivables/payables represent balances of the VIE and subsidiaries of the VIE due from/to the Company and the Group’s consolidated subsidiaries.

As of December 31, 2021, and June 30, 2022, there were no pledges or collateralization of the VIE and VIE’s subsidiaries’ assets that can only be used to settle obligations of the VIE and VIEs’ subsidiaries. The amounts of the net liabilities of the VIE and subsidiaries of the VIE were RMB556,022 and RMB769,398 (US$114,871) as of December 31, 2021, and June 30, 2022, respectively. The creditors of the VIE and subsidiaries of the VIE’s third-party liabilities did not have recourse to the general credit of the primary beneficiary in the normal course of business. The VIE holds certain assets, including detection equipment and related equipment for use in their operations. The Company did not provide nor intend to provide additional financial or other support not previously contractually required to the VIE and subsidiaries of the VIE during the periods presented.

XML

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission regarding financial reporting that are consistent with those used in the preparation of the Company’s audited consolidated financial statements for the year ended December 31, 2021. Accordingly, these unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by U.S. GAAP for annual financial statements.

The unaudited interim condensed financial statements have been prepared on the same basis as the audited consolidated financial statements for the year ended December 31, 2021 and, in the opinion of management, reflect all normal recurring adjustments, necessary to present a fair statement of the results for the interim periods presented. Results of the operations for the six months ended June 30, 2022 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2021.

The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.

Convenience translation

Translations of amounts from RMB into US$ for the convenience of the reader have been calculated at the exchange rate of RMB 6.6981 per US$1.00 on June 30, 2022, as published on the website of the United States Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at such rate or at any other rate.

Use of estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affected the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Areas where management uses subjective judgment include, but are not limited to, allowance for credit losses, inventory provision, standalone selling prices of performance obligations, the useful lives and impairment of long-lived assets, breakage income and incremental borrowing rates for lease liabilities. Management bases its estimates on historical experience and on assumptions that it believes are reasonable. Actual results could differ materially from those estimates.

Accounts receivable, contract assets and allowance for credit losses

The Group records the allowance for credit losses as an offset to accounts receivable and contract assets, with estimated credit losses charged to “General and administrative expenses” in the condensed consolidated statements of comprehensive loss. The Group assesses credit loss by reviewing accounts receivable and contract assets on a collective basis where similar characteristics exist, primarily based on similar business segments, service or product offerings and on an individual basis when the Group identifies specific customers with known disputes or collectability issues. The Group applies a migration roll rate method that considers historical collectability based on past due status, the age of the accounts receivable and contract asset balances, credit quality of the Group’s customers based on ongoing credit evaluations, current economic conditions, reasonable and supportable forecasts of future economic conditions and other factors that may affect the Group’s ability to collect from customers. The Group writes off accounts receivable and contract assets are deemed uncollectible when after all collection efforts have ceased.

Contract liabilities

The Group records a contract liability, which is presented as “deferred revenue” on the consolidated balance sheets when a customer pays consideration before the Group provides products or services.

Deferred revenue increased RMB20,222 (US$3,019) compared to the year ended December 31, 2021 is a result of the increase in consideration received from the Group’s customers. The Group receives payments from customers based on a billing schedule as established in contracts. Revenue recognized that was included in deferred revenue balance at the beginning of the period was RMB18,845 and RMB14,101(US$2,105) for the six months ended June 30, 2021 and 2022, respectively.

The transaction prices allocated to the remaining performance obligations (unsatisfied or partially satisfied) as of December 31, 2021 and June 30, 2022 were RMB199,354 and RMB 356,887(US$53,282), respectively. RMB203,955 (US$30,450) of transaction prices allocated to the remaining performance obligations which are expected to be recognized as revenue after one year are related to pharma research and development services. All the other amounts of transaction prices allocated to the remaining performance obligations are expected to be recognized as revenue within one year. The amounts disclosed above do not include variable consideration which is constrained.

Significant accounting policies

For a more complete discussion of the Company’s significant accounting policies and other information, the unaudited interim condensed consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report (Form 20-F) for the year ended December 31, 2021.

There have been no material changes to the Company’s significant accounting policies as of and for the six months ended June 30, 2022, as compared to the significant accounting policies described in the Annual Report.

XML

Segment Reporting

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Segment Reporting

3 SEGMENT REPORTING

The Group had three operating segments, including the central laboratory business, the in-hospital business and pharma research and development services for the six-months ended June 30, 2022 and 2021. The operating segments also represented the reporting segments. The Group’s CODM assesses the performance of the operating segments based on the measures of revenues, cost of revenue and gross profit by the central laboratory business, the in-hospital business and pharma research and development services. Other than the information provided below, the CODM does not use any other measures by segments.

Summarized information by segments for the six months ended June 30, 2022 and 2021 is as follows:

	For the six months ended June 30,2021												For the six months ended June 30,2022
	Central laboratory business			In-hospital business			Pharma research and development services			Total			Central laboratory business			In-hospital business			Pharma research and development services			Total
	RMB			RMB			RMB			RMB			RMB			RMB			RMB			RMB			US$
	(unaudited)			(unaudited)			(unaudited)			(unaudited)			(unaudited)			(unaudited)			(unaudited)			(unaudited)			(unaudited)
Revenues:
Revenues from services		154,560			8			9,846			164,414			152,808			2,345			30,428			185,581			27,707
Revenues from sales of products		—			69,488			—			69,488			—			80,789			—			80,789			12,061
Total revenues		154,560			69,496			9,846			233,902			152,808			83,134			30,428			266,370			39,768
Cost of revenues		(40,667	)		(20,000	)		(6,064	)		(66,731	)		(44,659	)		(29,726	)		(21,803	)		(96,188	)		(14,361	)
Gross profit		113,893			49,496			3,782			167,171			108,149			53,408			8,625			170,182			25,407

XML

Fair Value Measurements

6 Months Ended

Jun. 30, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements

4 FAIR VALUE MEASUREMENTS

The Group applies ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2—Includes other inputs that are directly or indirectly observable in the marketplace.

Level 3—Unobservable inputs which are supported by little or no market activity.

ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach; and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.

The carrying amounts of cash and cash equivalent, restricted cash, short-term investments, accounts receivable, amounts due from and due to related parties, accounts payable and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amounts of long-term borrowings and lease liabilities approximate their fair values since they bear interest at rates which approximate market interest rates.

The Group did not transfer any assets or liabilities in or out of Level 3 during the six months ended June 30, 2021 and 2022. As of December 31, 2021 and June 30, 2022, there was no warrants outstanding. Therefore, there was no asset or liability measured at fair value using Level 3 unobservable inputs on a recurring basis as of December 31, 2021 and June 30, 2022.

There were no financial assets and liabilities measured and recorded at fair value on a non-recurring basis as of December 31, 2021 and June 30, 2022.

XML

Accounts Receivable, Net

6 Months Ended

Jun. 30, 2022

Receivables [Abstract]

ACCOUNTS RECEIVABLE, NET

5 ACCOUNTS RECEIVABLE, NET

	As of
	December 31, 2021			June 30, 2022
	RMB			RMB			US$
				(unaudited)
Accounts receivable		131,363			145,783			21,765
Allowance for credit losses		(39,166	)		(44,823	)		(6,692	)
		92,197			100,960			15,073

The changes in the allowance for credit losses were as follows:

	For the six months ended June 30
	2021			2022
	RMB			RMB		US$
	(unaudited)			(unaudited)
Balance at beginning of the period		24,215			39,166		5,847
Adoption of ASC 326		11,358			—		—
Provisions		(937	)		5,657		845
Balance at end of the period		34,636			44,823		6,692

XML

Contract Assets

6 Months Ended

Jun. 30, 2022

Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]

CONTRACT ASSETS

6 CONTRACT ASSETS

	As of
	December 31, 2021			June 30, 2022
	RMB			RMB			US$
				(unaudited)
Contract assets		56,869			70,186			10,478
Allowance for credit losses		(14,478	)		(25,593	)		(3,821	)
		42,391			44,593			6,657

The changes in the allowance for credit losses were as follows:

	For the six months ended June 30
	2021		2022
	RMB		RMB		US$
			(unaudited)
Balance at beginning of the period		3,497		14,478		2,162
Adoption of ASC 326		2,383		—		—
Provisions		4,088		11,115		1,659
Balance at end of the period		9,968		25,593		3,821

XML

Inventories, Net

6 Months Ended

Jun. 30, 2022

Inventory Disclosure [Abstract]

Inventories, Net

7 INVENTORIES, NET

	As of
	December 31, 2021			June 30, 2022
	RMB			RMB			US$
				(unaudited)
Raw materials		82,455			90,957			13,580
Work in progress		7,902			10,220			1,526
Finished goods		35,481			38,095			5,687
Inventory provision		(2,628	)		(9,635	)		(1,438	)
		123,210			129,637			19,355

XML

Prepayments And Other Current Assets

6 Months Ended

Jun. 30, 2022

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepayments And Other Current Assets

8 PREPAYMENTS AND OTHER CURRENT ASSETS

	As of
	December 31, 2021		June 30, 2022
	RMB		RMB		US$
			(unaudited)
Deductible input VAT		23,232		17,828		2,663
Prepayments		30,695		10,746		1,605
Advance to employees		—		1,673		250
Deposits		1,874		2,158		322
Interest receivables		111		405		60
Employee loan (i)		3,500		—		—
Others (ii)		867		2,035		305
		60,279		34,845		5,205

(i) On March 16, 2021 the Group extended a loan to an employee with principal amount of RMB3,500 (US$523) at simple annual interest rate of 3.08%. The loan was repaid in February 2022.

(ii) Certain financial assets included in others, net of the allowance for credit losses of RMB95 and nil as of December 31, 2021 and June 30, 2022, respectively. Cumulative effect of adopting ASC 326 on January 1, 2021 of other current assets was RMB115 (US$17). Reversal of provision were RMB97 and RMB95 (US$14) for the six months ended June 30, 2021 and 2022, respectively.

XML

Property And Equipment, Net

6 Months Ended

Jun. 30, 2022

Property, Plant and Equipment [Abstract]

Property And Equipment, Net

9 PROPERTY AND EQUIPMENT, NET

Property and equipment consist of the following:

	As of
	December 31, 2021			June 30, 2022
	RMB			RMB			US$
				(unaudited)
Machinery and laboratory equipment		231,289			246,389			36,785
Vehicles		2,812			2,808			419
Furniture and tools		15,723			16,756			2,502
Electronic equipment		48,068			49,937			7,455
Leasehold improvements		161,037			161,691			24,140
Construction in progress		27,555			40,062			5,981
		486,484			517,643			77,282
Accumulated depreciation		(161,046	)		(216,394	)		(32,307	)
		325,438			301,249			44,975

Depreciation expenses recognized for the six months ended June 30, 2021 and 2022 were RMB20,614, and RMB57,953 (US$8,652), respectively. 

XML

Equity Forward

6 Months Ended

Jun. 30, 2022

Equity [Abstract]

Equity Forward

10 EQUITY FORWARD

On June 21, 2022, the Company’s board of directors authorized a share repurchase plan under which the Company may repurchase up to US$10,000 its Class A ordinary shares in the form of its ADS during a 12-month period (the “Share Repurchase Program”). The Company entered an accelerated share repurchase (“ASR”) agreement with Bank of America, pursuant to which it prepaid US$10,000 with the repurchase price determined by the volume-weighted average price (“VWAP”) of the Company’s ADS over the term of the ASR. The settlement date of this contract was August 23, 2022.

The Company evaluated and concluded the ASR agreement was an equity classified forward contract pursuant to ASC 815-40-25-10 and recognized the contract notional amount as contra-equity in the statement of changes in shareholder equity for the six months ended June 30, 2022

XML

Share-Based Compensation

6 Months Ended

Jun. 30, 2022

Share-based Payment Arrangement [Abstract]

Share-Based Compensation

11 SHARE-BASED COMPENSATION

Total share-based compensation expenses recognized for the six months ended June 30, 2021 and 2022 were as follows:

	For the six months ended June 30,
	2021		2022
	RMB		RMB		US$
	(unaudited)		(unaudited)
Cost of revenues		745		806		120
Research and development expenses		43,230		24,222		3,616
Selling and marketing expenses		5,442		3,932		587
General and administrative expenses		118,750		128,330		19,159
		168,167		157,290		23,483

XML

Income Taxes

6 Months Ended

Jun. 30, 2022

Income Tax Disclosure [Abstract]

Income Taxes

12 INCOME TAXES

For interim income tax reporting, the Group computed an estimate annual effective tax rate (“EAETR”) and apply it to year-to-date ordinary income (loss), exclusive of discrete items. Tax jurisdictions with a projected or year-to-date loss for which a tax benefit cannot be realized are excluded. The tax effects of unusual or infrequently occurring items, including changes in judgment about valuation allowances and effects of changes in tax laws or rates, are reported in the interim period in which they occur.

The Group recorded income tax expenses of RMB84 (US$13), representing effective tax rate of nil for the six months ended June 30, 2022 compared to RMB1,626 for the six months ended June 30, 2021. The primary difference between the PRC statutory tax rate of 15% for qualified high-tech enterprise and the effective tax rate for the six months ended June 30, 2022 are primarily due to permanent book to tax adjustments such as super R&D deduction netted with nondeductible entertainment expense and stock compensation expense.

As of June 30, 2022, there was no significant impact from tax uncertainties on the Group’s unaudited interim condensed consolidated financial statements. The Group did not record any interest and penalties related to an uncertain tax position for the six months ended June 30, 2021 and 2022. The Group does not expect the amount of unrecognized tax benefits would increase significantly in the next 12 months.

In general, the PRC tax authorities have up to five years to conduct examinations of the tax filings of the Company’s PRC subsidiaries, the VIE and the VIE’s subsidiaries. Accordingly, the PRC tax filings from 2017 through 2021 remain open to examination by the respective tax authorities. The Group may also be subject to the examinations of the tax filings in other jurisdictions, which are not material to the consolidated financial statements.

XML

Loss Per Share

6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Loss Per Share

13 LOSS PER SHARE

Basic and diluted loss per share for the six months ended June 30, 2021 and 2022 are calculated as follows:

	For the six months ended June 30,
	2021						2022
	Class A			Class B			Class A						Class B
	RMB			RMB			RMB			US$			RMB			US$
	(unaudited)						(unaudited)
Numerator:
Net loss attributable to ordinary shareholders		(312,635	)		(62,441	)		(436,882	)		(65,227	)		(86,643	)		(12,936	)
Denominator:
Weighted-average number of ordinary shares outstanding		87,470,332			17,324,848			87,909,137			87,909,137			17,324,848			17,324,848
Effect of unvested restricted shares		(727,452	)		—			(552,017	)		(552,017	)		—			—
Weighted average number of ordinary shares outstanding – basic and diluted		86,742,880			17,324,848			87,357,120			87,357,120			17,324,848			17,324,848
Loss per share - basic and diluted		(3.60	)		(3.60	)		(4.98	)		(0.74	)		(4.98	)		(0.74	)

For the six months ended June 30, 2021 and 2022, the two-class method was applied to the outstanding Class A and Class B ordinary shares. The unvested restricted shares were excluded from the computation of weighted-average number or ordinary shares outstanding because the Group is in a loss position and the holders of the restricted shares do not have an obligation to fund losses of the Group. The effects of all outstanding share options were excluded from the computation of diluted loss per share for the six months ended June 30, 2021 and 2022 as their effects would be anti-dilutive.

XML

Related Party Transactions

6 Months Ended

Jun. 30, 2022

Related Party Transactions [Abstract]

Related Party Transactions

14 RELATED PARTY TRANSACTIONS

a) Related parties

Name of related parties	Relationship
Yusheng Han	Shareholder of the shareholder of the Company, Chief Executive Officer and director
Shaokun Chuai	Shareholder of the shareholder of the Company, Chief Operating Officer and director
EaSuMed Holding Ltd.	Equity method investee
Guangzhou Burning Rock Biological Engineering Co., Ltd.	Company controlled by the Founder

b) The Group had the following related party balance at the end of the periods:

	As of
	December 31, 2021		June 30, 2022
	RMB		RMB		US$
			(unaudited)
EaSuMed Holding Ltd.		212		—		—
Total amounts due from related parties		212		—		—

All the balances with a related party as of December 31, 2021 were unsecured. All outstanding balances are repayable on demand unless otherwise disclosed. No allowance for credit losses was recognized for the amounts due from related parties for the six months ended June 30, 2021 and 2022.

c) The Group had the following related party transactions:

	For the six months ended June 30,
	2021		2022
	RMB		RMB		US$
	(unaudited)		(unaudited)
Consulting service received from:
EaSuMed Holding Ltd.		475		94		14
Rental income from:
Guangzhou Burning Rock Biological Engineering Co., Ltd.(i)		97		—		—
Equipment usage service income from:
Guangzhou Burning Rock Biological Engineering Co., Ltd.(ii)		237		—		—

(i) On April 1, 2021, the Group entered into a one-year sublease agreement on its office with a related party and recorded RMB97 in other income for the six month ended June 30, 2021. The lease was early terminated on September 30, 2021.

(ii) On April 1, 2021, the Group entered into a contract to provide equipment usage service to its related party with a total contact amount of RMB997, of which RMB237 was recorded in other income for the six month ended June 30, 2021. The contract was early terminated on September 30, 2021.

XML

Commitments and Contingencies

6 Months Ended

Jun. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

15 COMMITMENTS AND CONTINGENCIES

Capital expenditure commitments

The Group has capital expenditure commitments for the laboratory leasehold improvements of RMB6,520 (US$973) as of June 30, 2022, which are scheduled to be paid within one year.

Contingencies

The Group is currently not involved in any legal or administrative proceedings that may have a material adverse impact on the Group’s business, financial position or results of operations.

XML

Restricted Net Assets

6 Months Ended

Jun. 30, 2022

Restricted Net Assets [Abstract]

Restricted Net Assets

16 RESTRICTED NET ASSETS

Under the PRC laws and regulations, there are restrictions on the Company’s PRC subsidiaries and the VIE with respect to transferring certain of their net assets to the Company either in the form of dividends, loans, or advances. The Company’s restricted net assets from its PRC subsidiaries, the VIE and VIE’s subsidiaries, as determined pursuant to PRC GAAP, were RMB382,724 and RMB344,331 (US$51,407) as of December 31, 2021 and June 30, 2022, respectively.

XML

Subsequent Events

6 Months Ended

Jun. 30, 2022

Subsequent Events [Abstract]

Subsequent Events

17 SUBSEQUENT EVENTS

On August 23, 2022, the Company repurchased a total of 3,023,138 Class A ordinary shares in the form of ADSs upon settlement of the ASR program.

XML

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2022

Accounting Policies [Abstract]

Basis of presentation

Basis of presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission regarding financial reporting that are consistent with those used in the preparation of the Company’s audited consolidated financial statements for the year ended December 31, 2021. Accordingly, these unaudited interim condensed consolidated financial statements do not include all of the information and footnotes required by U.S. GAAP for annual financial statements.

The unaudited interim condensed financial statements have been prepared on the same basis as the audited consolidated financial statements for the year ended December 31, 2021 and, in the opinion of management, reflect all normal recurring adjustments, necessary to present a fair statement of the results for the interim periods presented. Results of the operations for the six months ended June 30, 2022 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2021.

The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.

Convenience translation

Convenience translation

Translations of amounts from RMB into US$ for the convenience of the reader have been calculated at the exchange rate of RMB 6.6981 per US$1.00 on June 30, 2022, as published on the website of the United States Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at such rate or at any other rate.

Use of estimates

Use of estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affected the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Areas where management uses subjective judgment include, but are not limited to, allowance for credit losses, inventory provision, standalone selling prices of performance obligations, the useful lives and impairment of long-lived assets, breakage income and incremental borrowing rates for lease liabilities. Management bases its estimates on historical experience and on assumptions that it believes are reasonable. Actual results could differ materially from those estimates.

Accounts receivable, contract assets and allowance for credit losses

Accounts receivable, contract assets and allowance for credit losses

The Group records the allowance for credit losses as an offset to accounts receivable and contract assets, with estimated credit losses charged to “General and administrative expenses” in the condensed consolidated statements of comprehensive loss. The Group assesses credit loss by reviewing accounts receivable and contract assets on a collective basis where similar characteristics exist, primarily based on similar business segments, service or product offerings and on an individual basis when the Group identifies specific customers with known disputes or collectability issues. The Group applies a migration roll rate method that considers historical collectability based on past due status, the age of the accounts receivable and contract asset balances, credit quality of the Group’s customers based on ongoing credit evaluations, current economic conditions, reasonable and supportable forecasts of future economic conditions and other factors that may affect the Group’s ability to collect from customers. The Group writes off accounts receivable and contract assets are deemed uncollectible when after all collection efforts have ceased.

Contract liabilities

Contract liabilities

The Group records a contract liability, which is presented as “deferred revenue” on the consolidated balance sheets when a customer pays consideration before the Group provides products or services.

Deferred revenue increased RMB20,222 (US$3,019) compared to the year ended December 31, 2021 is a result of the increase in consideration received from the Group’s customers. The Group receives payments from customers based on a billing schedule as established in contracts. Revenue recognized that was included in deferred revenue balance at the beginning of the period was RMB18,845 and RMB14,101(US$2,105) for the six months ended June 30, 2021 and 2022, respectively.

The transaction prices allocated to the remaining performance obligations (unsatisfied or partially satisfied) as of December 31, 2021 and June 30, 2022 were RMB199,354 and RMB 356,887(US$53,282), respectively. RMB203,955 (US$30,450) of transaction prices allocated to the remaining performance obligations which are expected to be recognized as revenue after one year are related to pharma research and development services. All the other amounts of transaction prices allocated to the remaining performance obligations are expected to be recognized as revenue within one year. The amounts disclosed above do not include variable consideration which is constrained.

XML

Organization (Tables)

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of financial information of VIE and VIE's subsidiaries

The following table sets forth the assets and liabilities of the VIE and subsidiaries of the VIE included in the Group’s unaudited interim condensed consolidated balance sheet:

	As of
	December 31, 2021		June 30, 2022
	RMB		RMB		US$
			(unaudited)
Cash and cash equivalents		185,850		332,367		49,621
Restricted cash		—		2,892		432
Accounts receivable (net of allowances of RMB38,922 and RMB44,566 (US$6,654) as of December 31, 2021 and June 30, 2022, respectively)		92,197		100,960		15,072
Contract assets		42,391		44,593		6,657
Inter-company receivables*		75,560		214,874		32,080
Inventories		119,257		120,952		18,058
Prepayments and other current assets		40,957		17,388		2,596
Total current assets		556,212		834,026		124,516
Property and equipment, net		42,623		58,285		8,702
Intangible assets, net		633		375		56
Other non-current assets		8,346		10,227		1,527
Operating right-of-use assets		51,630		41,875		6,252
Total non-current assets		103,232		110,762		16,537
TOTAL ASSETS		659,444		944,788		141,053
Accounts payable		27,102		19,925		2,975
Deferred revenue		133,489		163,095		24,349
Inter-company payables*		897,633		1,397,180		208,593
Accrued liabilities and other current liabilities		89,976		62,557		9,339
Customer deposits		972		484		72
Short-term borrowing		2,370		2,370		354
Current portion of operating lease liabilities		25,692		26,681		3,983
Total current liabilities		1,177,234		1,672,292		249,665
Deferred government grant
Other non-current liabilities		8,563		24,034		3,588
Non-current portion of operating lease liabilities		29,669		17,862		2,667
Total non-current liabilities		38,232		41,896		6,255
TOTAL LIABILITIES		1,215,466		1,714,188		255,920

* Inter-company receivables/payables represent balances of the VIE and subsidiaries of the VIE due from/to the Company and the Group’s consolidated subsidiaries.

XML

Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Summary of Segment Reporting Information

Summarized information by segments for the six months ended June 30, 2022 and 2021 is as follows:

	For the six months ended June 30,2021												For the six months ended June 30,2022
	Central laboratory business			In-hospital business			Pharma research and development services			Total			Central laboratory business			In-hospital business			Pharma research and development services			Total
	RMB			RMB			RMB			RMB			RMB			RMB			RMB			RMB			US$
	(unaudited)			(unaudited)			(unaudited)			(unaudited)			(unaudited)			(unaudited)			(unaudited)			(unaudited)			(unaudited)
Revenues:
Revenues from services		154,560			8			9,846			164,414			152,808			2,345			30,428			185,581			27,707
Revenues from sales of products		—			69,488			—			69,488			—			80,789			—			80,789			12,061
Total revenues		154,560			69,496			9,846			233,902			152,808			83,134			30,428			266,370			39,768
Cost of revenues		(40,667	)		(20,000	)		(6,064	)		(66,731	)		(44,659	)		(29,726	)		(21,803	)		(96,188	)		(14,361	)
Gross profit		113,893			49,496			3,782			167,171			108,149			53,408			8,625			170,182			25,407

XML

Accounts Receivable, Net (Tables)

6 Months Ended

Jun. 30, 2022

Receivables [Abstract]

Summary of Account Receivable

	As of
	December 31, 2021			June 30, 2022
	RMB			RMB			US$
				(unaudited)
Accounts receivable		131,363			145,783			21,765
Allowance for credit losses		(39,166	)		(44,823	)		(6,692	)
		92,197			100,960			15,073

Summary of Movement in the Allowances for Doubtful Accounts

The changes in the allowance for credit losses were as follows:

	For the six months ended June 30
	2021			2022
	RMB			RMB		US$
	(unaudited)			(unaudited)
Balance at beginning of the period		24,215			39,166		5,847
Adoption of ASC 326		11,358			—		—
Provisions		(937	)		5,657		845
Balance at end of the period		34,636			44,823		6,692

XML

Contract Assets - (Tables)

6 Months Ended

Jun. 30, 2022

Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]

Schedule of Contract With Customer Asset Net Current

	As of
	December 31, 2021			June 30, 2022
	RMB			RMB			US$
				(unaudited)
Contract assets		56,869			70,186			10,478
Allowance for credit losses		(14,478	)		(25,593	)		(3,821	)
		42,391			44,593			6,657

Schedule of provision for contract assets and allowance for credit losses

The changes in the allowance for credit losses were as follows:

	For the six months ended June 30
	2021		2022
	RMB		RMB		US$
			(unaudited)
Balance at beginning of the period		3,497		14,478		2,162
Adoption of ASC 326		2,383		—		—
Provisions		4,088		11,115		1,659
Balance at end of the period		9,968		25,593		3,821

XML

Inventories, Net (Tables)

6 Months Ended

Jun. 30, 2022

Inventory, Work in Process and Raw Materials [Abstract]

Summary of Inventories

	As of
	December 31, 2021			June 30, 2022
	RMB			RMB			US$
				(unaudited)
Raw materials		82,455			90,957			13,580
Work in progress		7,902			10,220			1,526
Finished goods		35,481			38,095			5,687
Inventory provision		(2,628	)		(9,635	)		(1,438	)
		123,210			129,637			19,355

XML

Prepayments And Other Current Assets (Tables)

6 Months Ended

Jun. 30, 2022

Deferred Costs Capitalized Prepaid And Other Assets [Abstract]

Summary of Prepayments and Other Current Assets

	As of
	December 31, 2021		June 30, 2022
	RMB		RMB		US$
			(unaudited)
Deductible input VAT		23,232		17,828		2,663
Prepayments		30,695		10,746		1,605
Advance to employees		—		1,673		250
Deposits		1,874		2,158		322
Interest receivables		111		405		60
Employee loan (i)		3,500		—		—
Others (ii)		867		2,035		305
		60,279		34,845		5,205

(i) On March 16, 2021 the Group extended a loan to an employee with principal amount of RMB3,500 (US$523) at simple annual interest rate of 3.08%. The loan was repaid in February 2022.

(ii) Certain financial assets included in others, net of the allowance for credit losses of RMB95 and nil as of December 31, 2021 and June 30, 2022, respectively. Cumulative effect of adopting ASC 326 on January 1, 2021 of other current assets was RMB115 (US$17). Reversal of provision were RMB97 and RMB95 (US$14) for the six months ended June 30, 2021 and 2022, respectively.

XML

Property And Equipment, Net (Tables)

6 Months Ended

Jun. 30, 2022

Property, Plant and Equipment [Abstract]

Summary of property and equipment

Property and equipment consist of the following:

	As of
	December 31, 2021			June 30, 2022
	RMB			RMB			US$
				(unaudited)
Machinery and laboratory equipment		231,289			246,389			36,785
Vehicles		2,812			2,808			419
Furniture and tools		15,723			16,756			2,502
Electronic equipment		48,068			49,937			7,455
Leasehold improvements		161,037			161,691			24,140
Construction in progress		27,555			40,062			5,981
		486,484			517,643			77,282
Accumulated depreciation		(161,046	)		(216,394	)		(32,307	)
		325,438			301,249			44,975

XML

Share-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2022

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]

Summary of share-based compensation expenses

Total share-based compensation expenses recognized for the six months ended June 30, 2021 and 2022 were as follows:

	For the six months ended June 30,
	2021		2022
	RMB		RMB		US$
	(unaudited)		(unaudited)
Cost of revenues		745		806		120
Research and development expenses		43,230		24,222		3,616
Selling and marketing expenses		5,442		3,932		587
General and administrative expenses		118,750		128,330		19,159
		168,167		157,290		23,483

XML

Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

Basic and diluted loss per share for the six months ended June 30, 2021 and 2022 are calculated as follows:

	For the six months ended June 30,
	2021						2022
	Class A			Class B			Class A						Class B
	RMB			RMB			RMB			US$			RMB			US$
	(unaudited)						(unaudited)
Numerator:
Net loss attributable to ordinary shareholders		(312,635	)		(62,441	)		(436,882	)		(65,227	)		(86,643	)		(12,936	)
Denominator:
Weighted-average number of ordinary shares outstanding		87,470,332			17,324,848			87,909,137			87,909,137			17,324,848			17,324,848
Effect of unvested restricted shares		(727,452	)		—			(552,017	)		(552,017	)		—			—
Weighted average number of ordinary shares outstanding – basic and diluted		86,742,880			17,324,848			87,357,120			87,357,120			17,324,848			17,324,848
Loss per share - basic and diluted		(3.60	)		(3.60	)		(4.98	)		(0.74	)		(4.98	)		(0.74	)

XML

Related Party Transactions (Tables)

6 Months Ended

Jun. 30, 2022

Related Party Transactions [Abstract]

Summary of Relationship With Related Party

a) Related parties

Name of related parties	Relationship
Yusheng Han	Shareholder of the shareholder of the Company, Chief Executive Officer and director
Shaokun Chuai	Shareholder of the shareholder of the Company, Chief Operating Officer and director
EaSuMed Holding Ltd.	Equity method investee
Guangzhou Burning Rock Biological Engineering Co., Ltd.	Company controlled by the Founder

Summary of Related Party Balances

b) The Group had the following related party balance at the end of the periods:

	As of
	December 31, 2021		June 30, 2022
	RMB		RMB		US$
			(unaudited)
EaSuMed Holding Ltd.		212		—		—
Total amounts due from related parties		212		—		—

Summary of Related Party Transactions

c) The Group had the following related party transactions:

	For the six months ended June 30,
	2021		2022
	RMB		RMB		US$
	(unaudited)		(unaudited)
Consulting service received from:
EaSuMed Holding Ltd.		475		94		14
Rental income from:
Guangzhou Burning Rock Biological Engineering Co., Ltd.(i)		97		—		—
Equipment usage service income from:
Guangzhou Burning Rock Biological Engineering Co., Ltd.(ii)		237		—		—

(i) On April 1, 2021, the Group entered into a one-year sublease agreement on its office with a related party and recorded RMB97 in other income for the six month ended June 30, 2021. The lease was early terminated on September 30, 2021.

(ii) On April 1, 2021, the Group entered into a contract to provide equipment usage service to its related party with a total contact amount of RMB997, of which RMB237 was recorded in other income for the six month ended June 30, 2021. The contract was early terminated on September 30, 2021.

XML

Organization - Summary of Financial Information of VIE and VIE's Subsidiaries (Detail) ¥ in Thousands, $ in Thousands		Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 CNY (¥)	Jun. 30, 2021 CNY (¥)
Table Text Block Supplement [Abstract]
Cash and cash equivalents		¥ 1,148,597	$ 171,481	¥ 1,431,317	¥ 1,852,927
Restricted cash		4,453	665	7,795	¥ 30,338
Accounts receivable (net of allowances of RMB38,922 and RMB44,566 (US$6,654) as of December 31, 2021 and June 30, 2022, respectively)		100,960	15,073	92,197
Contract assets		44,593	6,657	42,391
Inventories		129,637	19,355	123,210
Prepayments and other current assets		34,845	5,205	60,279
Total current assets		1,463,085	218,436	1,820,946
Property and equipment, net		301,249	44,975	325,438
Intangible assets, net		3,354	500	5,150
Other non-current assets		21,198	3,165	45,136
Operating right-of-use assets		66,655	9,951	81,007
Total non-current assets		398,189	59,446	457,641
TOTAL ASSETS		1,861,274	277,882	2,278,587
Accounts payable		56,495	8,434	63,080
Deferred revenue		163,093	24,349	142,871
Customer deposits		1,052	157	972
Short-term borrowings		2,370	354	2,370
Current portion of operating lease liabilities		38,005	5,674	34,999
Total current liabilities		359,450	53,664	372,184
Other non-current liabilities		37,242	4,830	11,776
Total non-current liabilities		69,591	10,390	61,092
Non-current portion of operating lease liabilities		32,349	5,560	49,316
TOTAL LIABILITIES		429,041	64,054	433,276
VIE and VIE's subsidiaries
Table Text Block Supplement [Abstract]
Cash and cash equivalents		332,367	49,621	185,850
Restricted cash		2,892	432	0
Accounts receivable (net of allowances of RMB38,922 and RMB44,566 (US$6,654) as of December 31, 2021 and June 30, 2022, respectively)		100,960	15,072	92,197
Contract assets		44,593	6,657	42,391
Inter-company receivables	[1]	214,874	32,080	75,560
Inventories		120,952	18,058	119,257
Prepayments and other current assets		17,388	2,596	40,957
Total current assets		834,026	124,516	556,212
Property and equipment, net		58,285	8,702	42,623
Intangible assets, net		375	56	633
Other non-current assets		10,227	1,527	8,346
Operating right-of-use assets		41,875	6,252	51,630
Total non-current assets		110,762	16,537	103,232
TOTAL ASSETS		944,788	141,053	659,444
Accounts payable		19,925	2,975	27,102
Deferred revenue		163,095	24,349	133,489
Inter-company payables	[1]	1,397,180	208,593	897,633
Accrued liabilities and other current liabilities		62,557	9,339	89,976
Customer deposits		484	72	972
Short-term borrowings		2,370	354	2,370
Current portion of operating lease liabilities		26,681	3,983	25,692
Total current liabilities		1,672,292	249,665	1,177,234
Other non-current liabilities		24,034	3,588	8,563
Total non-current liabilities		41,896	6,255	38,232
Non-current portion of operating lease liabilities		17,862	2,667	29,669
TOTAL LIABILITIES		¥ 1,714,188	$ 255,920	¥ 1,215,466

[1] Inter-company receivables/payables represent balances of the VIE and subsidiaries of the VIE due from/to the Company and the Group’s consolidated subsidiaries.

XML

Organization - Summary of Financial Information of VIE and VIE's Subsidiaries (Parenthetical) (Detail) ¥ in Thousands, $ in Thousands	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 CNY (¥)
Table Text Block Supplement [Abstract]
Accounts Receivable, Allowance	¥ 44,823	$ 6,692	¥ 39,166
Variable Interest Entity, Primary Beneficiary [Member]
Table Text Block Supplement [Abstract]
Accounts Receivable, Allowance	¥ 44,566	$ 6,654	¥ 38,922

XML

Organization - Additional Information (Detail) ¥ in Thousands, $ in Thousands	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 CNY (¥)
VIEs And Subsidiaries Of VIEs [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net Liabilities	¥ 769,398	$ 114,871	¥ 556,022

XML

Summary of Significant Accounting Policies - Additional Information (Detail) ¥ in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 CNY (¥)
Convenience translation rate	6.6981			6.6981
Increase decrease in deferred revenue	¥ 20,222	$ 3,019	¥ 27,115
Deferred revenue recognized	14,101	$ 2,105	¥ 18,845
Remaining performance obligation	356,887			$ 53,282	¥ 199,354
After One Year [Member]
Remaining performance obligation	¥ 203,955			$ 30,450

XML

Segment Reporting - Summary of Segment Reporting Information (Detail) ¥ in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)
Revenues:
Revenues from services	¥ 185,581	$ 27,707	¥ 164,414
Revenues from sales of products	80,789	12,061	69,488
Total revenues	266,370	39,768	233,902
Cost of revenues:	(96,188)	(14,361)	(66,731)
Gross profit	170,182	$ 25,407	167,171
Central laboratory business
Revenues:
Revenues from services	152,808		154,560
Revenues from sales of products	0		0
Total revenues	152,808		154,560
Cost of revenues:	(44,659)		(40,667)
Gross profit	108,149		113,893
In-hospital business
Revenues:
Revenues from services	2,345		8
Revenues from sales of products	80,789		69,488
Total revenues	83,134		69,496
Cost of revenues:	(29,726)		(20,000)
Gross profit	53,408		49,496
Pharma research and development services
Revenues:
Revenues from services	30,428		9,846
Revenues from sales of products	0		0
Total revenues	30,428		9,846
Cost of revenues:	(21,803)		(6,064)
Gross profit	¥ 8,625		¥ 3,782

XML

Fair Value Measurements - Additional Information (Detail) - Fair Value, Recurring [Member] - CNY (¥) ¥ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	¥ 0	¥ 0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	0	0
Liabilities, Fair Value Disclosure	¥ 0	¥ 0

XML

Accounts Receivable, Net - Summary of Account Receivable (Detail) ¥ in Thousands, $ in Thousands	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 CNY (¥)
Receivables [Abstract]
Accounts receivable	¥ 145,783	$ 21,765	¥ 131,363
Allowance for credit losses	(44,823)	(6,692)	(39,166)
Accounts Receivable, Net	¥ 100,960	$ 15,073	¥ 92,197

XML

Accounts Receivable, Net - Summary of Movement in the Allowances for Doubtful Accounts (Detail) ¥ in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)
Accounts Receivable Allowance For Credit Loss [Line Items]
Balance at beginning of the period	¥ 39,166	$ 5,847	¥ 24,215
Provisions	5,657	845	(937)
Balance at end of the period	44,823	6,692	34,636
Accounting Standards Update 2016-13 [Member]
Accounts Receivable Allowance For Credit Loss [Line Items]
Adoption of ASC 326	¥ 0	$ 0	¥ 11,358

XML

Contract Assets - Schedule of Contract With Customer Asset Net Current (Details) ¥ in Thousands, $ in Thousands	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 CNY (¥)	Dec. 31, 2021 USD ($)	Jun. 30, 2021 CNY (¥)	Dec. 31, 2020 CNY (¥)
Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]
Contract assets	¥ 70,186	$ 10,478	¥ 56,869
Allowance for credit losses	(25,593)	(3,821)	(14,478)	$ (2,162)	¥ (9,968)	¥ (3,497)
Total	¥ 44,593	$ 6,657	¥ 42,391

XML

Contract Assets - Schedule of provision for contract assets and allowance for credit losses (Details) ¥ in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)
Schedule of provision for contract assets and allowance for credit losses [Line Items]
Balance at beginning of the period	¥ 14,478	$ 2,162	¥ 3,497
Provisions	11,115	1,659	4,088
Balance at end of the period	25,593	3,821	9,968
Accounting Standards Update 2016-13 [Member]
Schedule of provision for contract assets and allowance for credit losses [Line Items]
Adoption of ASC 326	¥ 0	$ 0	¥ 2,383

XML

Inventories, Net - Summary of Inventories (Detail) ¥ in Thousands, $ in Thousands	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 CNY (¥)
Inventory, Work in Process and Raw Materials [Abstract]
Raw materials	¥ 90,957	$ 13,580	¥ 82,455
Work in progress	10,220	1,526	7,902
Finished goods	38,095	5,687	35,481
Inventory provision	(9,635)	(1,438)	(2,628)
Inventory, Net	¥ 129,637	$ 19,355	¥ 123,210

XML

Prepayments And Other Current Assets - Summary of Prepayments And Other Current Assets (Detail) ¥ in Thousands, $ in Thousands	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 CNY (¥)
Deferred Costs Capitalized Prepaid And Other Assets [Abstract]
Deductible input VAT	¥ 17,828	$ 2,663	¥ 23,232
Prepayments	10,746	1,605	30,695
Advance to employees	1,673	250	0
Deposits	2,158	322	1,874
Interest receivables	405	60	111
Employee loan (i)	0	0	3,500
Others	2,035	305	867
Prepayments and other Current Asset	¥ 34,845	$ 5,205	¥ 60,279

XML

Prepayments And Other Current Assets - Summary of Prepayments And Other Current Assets (Parenthetical) (Detail) ¥ in Thousands, $ in Thousands				6 Months Ended
	Mar. 16, 2021 CNY (¥)	Jan. 01, 2021 CNY (¥)	Jan. 01, 2021 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)	Dec. 31, 2021 CNY (¥)	Mar. 16, 2021 USD ($)
Deferred Costs Capitalized Prepaid And Other Assets [Line Items]
Principal amount of loan to an employee	¥ 3,500							$ 523
Annual interest rate	3.08%
Allowance for credit losses on other current assets							¥ 95
Reversal Of Provision				¥ 95	$ 14
Allowance For Doubtful Accounts Other Receivable Write Offs						¥ 97
Accounting Standards Update [Member]
Deferred Costs Capitalized Prepaid And Other Assets [Line Items]
Cumulative effect of adopting accounting standard update on the opening balnace of other current assets		¥ 115	$ 17

XML

Property And Equipment, Net - Summary of Property And Equipment Consist of The Following (Detail) ¥ in Thousands, $ in Thousands	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 CNY (¥)
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	¥ 517,643	$ 77,282	¥ 486,484
Accumulated depreciation	(216,394)	(32,307)	(161,046)
Property, Plant and Equipment, Net	301,249	44,975	325,438
Machinery And Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	246,389	36,785	231,289
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	2,808	419	2,812
Furniture And Tools [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	16,756	2,502	15,723
Electronic Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	49,937	7,455	48,068
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	161,691	24,140	161,037
Construction In Progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	¥ 40,062	$ 5,981	¥ 27,555

XML

Property And Equipment, Net - Additional Information (Detail) ¥ in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)
Depreciation	¥ 57,953	$ 8,652	¥ 20,614

XML

Equity Forward - Additional Information (Detail) $ in Thousands	Jun. 21, 2022 USD ($)
Equity [Abstract]
Stock repurchase program, authorized amount	$ 10,000
Stock repurchase program, period in force	12 months
Accelerated share repurchases, settlement payment or receipt	$ 10,000
Accelerated share repurchase program, settlement date	Aug. 23, 2022

XML

Share-Based Compensation - Summary of Share-Based Compensation Expenses (Detail) ¥ in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	¥ 157,290	$ 23,483	¥ 168,167
Cost of Revenues [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	806	120	745
Research and Development Expenses [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	24,222	3,616	43,230
Selling and Marketing Expenses [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	3,932	587	5,442
General and Administrative Expenses [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	¥ 128,330	$ 19,159	¥ 118,750

XML

Income Taxes - Additional Information (Detail) ¥ in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)
Income tax rate	15.00%	15.00%
Unrecognized Tax Benefits	¥ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	0		¥ 0
Income Tax Expense (Benefit)	¥ 84	$ 13	¥ 1,626
Effective Income Tax Rate Reconciliation, Percent	0.00%	0.00%
CHINA
Operating Loss Carryforwards, Expiration Term	5 years	5 years

XML

Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Detail) ¥ / shares in Units, $ / shares in Units, ¥ in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2022 CNY (¥) ¥ / shares shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 CNY (¥) ¥ / shares shares
Common Class A [Member]
Denominator:
Weighted average shares outstanding used in loss per share - basic	87,357,120	87,357,120	86,742,880
Weighted average shares outstanding used in loss per share - diluted	87,357,120	87,357,120	86,742,880
Loss per share - basic | (per share)	¥ (4.98)	$ (0.74)	¥ (3.6)
Loss per share - diluted | (per share)	¥ (4.98)	$ (0.74)	¥ (3.6)
Common Class B [Member]
Denominator:
Weighted average shares outstanding used in loss per share - basic	17,324,848	17,324,848	17,324,848
Weighted average shares outstanding used in loss per share - diluted	17,324,848	17,324,848	17,324,848
Loss per share - basic | (per share)	¥ (4.98)	$ (0.74)	¥ (3.6)
Loss per share - diluted | (per share)	¥ (4.98)	$ (0.74)	¥ (3.6)
Common Stock | Common Class A [Member]
Numerator:
Net loss attributable to ordinary shareholders	¥ (436,882)	$ (65,227)	¥ (312,635)
Denominator:
Weighted-average number of ordinary shares outstanding	87,909,137	87,909,137	87,470,332
Effect of unvested restricted shares	(552,017)	(552,017)	(727,452)
Common Stock | Common Class B [Member]
Numerator:
Net loss attributable to ordinary shareholders	¥ (86,643)	$ (12,936)	¥ (62,441)
Denominator:
Weighted-average number of ordinary shares outstanding	17,324,848	17,324,848	17,324,848
Effect of unvested restricted shares	0	0	0

XML

Related Party Transactions - Summary of Relationship With Related Party (Detail)	6 Months Ended
	Jun. 30, 2022
Yusheng Han
Related Party Transaction [Line Items]
Nature of Common Ownership or Management Control Relationships	Shareholder of the shareholder of the Company, Chief Executive Officer and director
Shaokun Chuai
Related Party Transaction [Line Items]
Nature of Common Ownership or Management Control Relationships	Shareholder of the shareholder of the Company, Chief Operating Officer and director
EaSuMed Holding Ltd [Member]
Related Party Transaction [Line Items]
Nature of Common Ownership or Management Control Relationships	Equity method investee
Guangzhou Burning Rock Biological Engineering Co., Ltd.
Related Party Transaction [Line Items]
Nature of Common Ownership or Management Control Relationships	Company controlled by the Founder

XML

Related Party Transactions - Summary of Related Party Balances (Detail) ¥ in Thousands, $ in Thousands	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 CNY (¥)
Amount due from a related party:
Amounts due from related parties	¥ 0	$ 0	¥ 212
EaSuMed Holding Ltd [Member]
Amount due from a related party:
Amounts due from related parties	¥ 0	$ 0	¥ 212

XML

Related Party Transactions - Summary of Related Party Transactions (Detail) ¥ in Thousands, $ in Thousands		6 Months Ended
		Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)
Related Party Transaction [Line Items]
Rental income from:				¥ 334
EaSuMed Holding Ltd [Member]
Related Party Transaction [Line Items]
Consulting service received from:		¥ 94	$ 14	475
Guangzhou Burning Rock Biological Engineering Co., Ltd
Related Party Transaction [Line Items]
Rental income from:	[1]			97
Equipment usage service income from:	[2]			¥ 237

[1] On April 1, 2021, the Group entered into a one-year sublease agreement on its office with a related party and recorded RMB97 in other income for the six month ended June 30, 2021. The lease was early terminated on September 30, 2021.

[2] On April 1, 2021, the Group entered into a contract to provide equipment usage service to its related party with a total contact amount of RMB997, of which RMB237 was recorded in other income for the six month ended June 30, 2021. The contract was early terminated on September 30, 2021.

XML

Related Party Transactions - Summary of Related Party Transactions (Parenthetical) (Detail) ¥ in Thousands, $ in Thousands		6 Months Ended
	Apr. 01, 2021 CNY (¥)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)
Related Party Transaction [Line Items]
Other income related party		¥ 425	$ 63	¥ 551
Guangzhou Burning Rock Biological Engineering Co., Ltd
Related Party Transaction [Line Items]
Total Contract Amount of Equipment Usage Service Related Party	¥ 997
Other income related party				¥ 237

XML

Related Party Transactions - Additional Information (Detail) ¥ in Thousands	Apr. 01, 2021 CNY (¥)
Guangzhou Burning Rock Biological Engineering Co Ltd. [Member] | Office Sublease Agreement [Member]
Sublease Income	¥ 97

XML

Commitments and Contingencies - Additional Information (Detail) - 6 months ended Jun. 30, 2022 ¥ in Thousands, $ in Thousands	CNY (¥)	USD ($)
Capital Addition [Member] | Leasehold Improvements [Member]
Long-term Purchase Commitment [Line Items]
Capital expenditure commitment	¥ 6,520	$ 973

XML

Restricted Net Assets - Additional Information (Detail) ¥ in Thousands, $ in Thousands	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 CNY (¥)
PRC Subsidiaries [Member]
Restricted Net Assets [Line Items]
Restricted net assets			¥ 382,724
VIE And VIE Subsidiaries [Member]
Restricted Net Assets [Line Items]
Restricted net assets	¥ 344,331	$ 51,407

XML

Subsequent Events - Additional Information (Detail)	Aug. 23, 2022 shares
Subsequent event [Member] | Accelerated share repurchase program [Member] | Class A common shares in the form of ADS [Member]
Subsequent Event [Line Items]
Stock repurchased during period, Shares	3,023,138